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Abstract 
  
 Family history of diabetes (FHD) has been recognized over the years as an 
important risk factor of the disease. Thus herein we evaluate the importance of FHD in 
the development of the three more prevalent types of diabetes, namely type 1 diabetes 
(T1D), Latent autoimmune diabetes of adults (LADA) and type 2 diabetes. 
 Our research study can be divided in two different parts: study 1, a clinico-
epidemiological study with a sample of 16.874 clinic files of people with diabetes (T1D, 
LADA and T2D); study 2, a preliminary clinic study with 23 siblings of type 2 diabetic 
patients. The metabolic profile of siblings was assessed with the performance of a 
modified OGTT with blood collections (0, 30, 90 and 120 mins).  
 The results of study 1 indicated that the presence of a sibling with T1D or a 
sibling with T2D is the high risk factor among FHD to develop T1D (14-fold) or T2D 
(6-fold), respectively. The high risk factor to develop LADA is the presence of different 
types of diabetes in parents (11-fold). The study 1 also indicated that type 2 diabetes 
was the prevalent type of diabetes among the siblings of each type of people with 
diabetes evaluated. Thus, in study 2 we addressed the hypothesis that siblings of type 2 
diabetics have a risk to develop diabetes and for that we evaluated their metabolic 
profile. The results of this study indicated a high prevalence of obesity among the 
siblings-T2D, mainly visceral, high levels of LDL-cholesterol, low levels of HDL-
cholesterol as well as high prevalence of fatty liver disease. These features can be 
related with a lower decrease of hepatic insulin clearance in the first 30 minutes of the 
OGTT. 
 It was concluding that presence of diabetes in siblings is the high risk factor to 
develop T1D and T2D, and this fact can be related with impairment in hepatic insulin 
clearance process. 
Keywords 
Family History of Diabetes; First-degree relatives ; Siblings; Diabetes Mellitus; Insulin 
Clearance; Modified OGTT. 
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Sumário 
 A presença de história familiar de diabetes (HFD) está descrita como um factor 
de risco importante para o desenvolvimento da doença. A HFD representa uma 
informação genómica valiosa porque caracteriza as interacções combinadas entre os 
factores ambientais, comportamentais e genéticos. Este é também um factor que tem 
apresentado elevada variabilidade entre populações, sendo de esta forma fundamental 
caracterizar a HFD de uma amostra da população portuguesa - pacientes da maior 
clínica de diabetes em Portugal, a Associação Protectora dos Diabéticos de Portugal 
(APDP).   
 O presente trabalho de investigação cientifica pode ser dividido em duas partes: 
estudo 1, foi um estudo clínico/epidemiológico, que consistiu na analise da HFD dos 
pacientes acompanhados na APDP num período de 5 anos (2009-2013). A amostra foi 
composta por um total de 16.874 fichas clínicas, englobando pessoas com diabetes tipo 
1 (n=3013), pessoas com diabetes Latente Autoimune do Adulto (n=373) e pessoas com 
diabetes tipo 2 (n = 13488); e estudo 2, - um estudo clinico preliminar, com uma 
amostra de 23 irmãos de pessoas com diabetes tipo 2. O perfil metabólico de resposta a 
uma prova modificada de tolerância oral à glicose foi avalaliado ao longo do tempo em  
com 4 pontos escolhidos previamente (0, 30, 90, 120 minutos).  
 No estudo 1, foi observado que o maior risco em termos de HFD de primeiro 
grau para o desenvolvimento de diabetes tipo 1 é a presença de um irmão com diabetes 
tipo 1 (14 vezes), enquanto o factor familiar de maior risco para o desenvolvimento de 
diabetes tipo 2 é a presença de um irmão com diabetes tipo 2 (6 vezes). Nos indivíduos 
com LADA foi detectado que o maior risco de desenvolver este tipo de diabetes, ocorre 
na presença de pais com diabetes de diferentes tipos. Foi também interessante observar 
as respetivas médias de idade do aparecimento dos três tipos de diabetes que se ajustam 
ao já observado na literatura. Tendo em conta estes resultados, nomeadamente a 
importância do parentesco entre irmãos constituir um fator de risco para a ocorrência de 
diabetes, e ainda pelo facto de a prevalência de irmãos com diabetes tipo 2 ser mais 
elevada em todos os tipos de pacientes analisados, foi decidido proceder-se ao estudo 2. 
Ou seja, com o estudo 1 foi possível perceber quais os grupos de maior risco para 
desenvolver a doença, enquanto que com o estudo 2 foram analisadas possíveis 
alterações metabólicas  associadas a um elevado risco de desenvolver diabetes que pode 
ser detectado nos irmãos de pessoas com diabetes tipo 2. Os resultados dos estudos 
xiii 
 
revelaram uma elevada prevalência de obesidade, principalmente de tipo visceral, níveis 
elevados de colesterol LDL e níveis baixos de colesterol HDL, bem como uma 
prevalência de perto de 100 % de esteatose hepática. Estas alterações metabólicas que 
estão intrinsecamente ligadas à diabetes tipo 2 parecem estar relacionadas com uma 
menor diminuição da clearance nos primeiros 30 minutos da prova de tolerância à 
glicose oral.  
 Este estudo permitiu concluir que os irmãos das pessoas com diabetes tipo 2 são 
de facto um grupo de risco para o desenvolvimento da doença, e que as diversas 
alterações metabólicas parecem estar relacionadas com um funcionamento inadequado 
do processo de clearance da insulina.  
 
Palavras-chave 
Historia Familiar de Diabetes; Parentes de primeiro grau; Irmãos; Diabetes Mellitus; 
Clearance da insulina; PTGO 
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1. State of the art 
 1.1 Glucose Homeostasis 
Glucose is an essential metabolic substrate of all mammalian cells. Glucose is 
the major carbohydrate presented to the cell for energy production and many other 
metabolic requirements. Glucose and other monosaccharides are transported across the 
intestinal wall to the hepatic portal vein and then to liver cells and other tissues. Then, 
they are converted to fatty acids, amino acids, and glycogen, or are oxidized by the 
various catabolic pathways of cells to generate energy necessary to supply all the 
metabolic process. The low blood concentrations of glucose can causes seizures, loss of 
consciousness, and death. However, long lasting elevation of blood glucose 
concentrations, can result in, renal failure, blindness, neuropathy and vascular disease. 
Therefore, blood glucose concentrations need to be maintained within narrow limits. 
The process of maintaining blood glucose at a steady-state level is called glucose 
homeostasis (Wood et al., 2003). 
 Although several factors are involved in regulation of carbohydrate metabolism 
(Fig 1), this physiological process is mainly maintained through the antagonistic action 
of two polypeptide hormones: glucagon and insulin. The liver is the major metabolic 
regulatory organ. About 80% of all circulating glucose that not derived directly from the 
diet comes from the liver. Glycogenolysis, the breakdown of glycogen (the polymerized 
storage form of glucose) and gluconeogenesis (the formation of glucose primarily from 
lactate and amino acids during the fasting state) are hepatic processes under the control 
of glucagon resulting in elevated plasma glucose levels. Insulin has the opposite effect 
by promoting the uptake of glucose by cells, mainly in liver, muscle and adipose tissue, 
with consequently decrease of glucose levels. There are a number of external signals 
that can contribute to insulin release, particularly increase in plasma glucose levels. 
There is considerable clinical interest in the mechanism and control of insulin secretion 
because this process normally declines during the onset of insulin resistance that leads 
to develop of diabetes (Huang et al., 2007). 
Plasma glucose concentration is a function that depends on the glucose entering 
in the circulation balanced by the rate of glucose that is remove from the circulation. 
Circulating glucose is derived essentially from three sources: intestinal absorption 
during the fed state, glycogenolysis, and gluconeogenesis. The factor determinant of 
how quickly glucose appears in the circulation during the fed state is the rate of gastric 
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emptying. During the fasting state glycogenolysis and gluconeogenesis are partly under 
the control of glucagon. After a meal, the glucose levels depend especially of insulin 
action in the several tissues. Thus, all these processes in order to maintain glucose 
within a narrow range, are regulated by the effect of different glucoregulatory hormones 
that include insulin, glucagon, amylin, glucagon-like peptide-1 (GLP-1), glucose-
dependent insulinotropic peptide (GIP), epinephrine, cortisol, and growth hormone. Of 
these, insulin and amylin are derived from the β-cells, glucagon from the α-cells of the 
pancreas, and GLP-1 and GIP from the L-cells of the intestine (Shrayyef, 2010).   
 
Figure 1– Plasma glucose: primary hormonal control. GLP-1 inhibits the production of glucagon in α-cell 
and stimulates the production of insulin by β-cell. Insulin inhibits the production of glucose by liver and 
promotes the uptake of glucose in insulin-dependent tissues like adipose tissue and skeletal muscle. 
Glucagon promotes the production of glucose in liver by glycogenolysis and gluconeogenesis (Adapted 
from Drucker, 2006).    
 
 In the fasting state, glucose leaves the circulation at a constant rate. With the 
aim to compensate the decrease of glucose levels, endogenous glucose need to be 
produce. The liver is responsible for approximately 80% of glucose release into the 
circulation in the post-absorptive state, via glycogenolysis and gluconeogenesis. Under 
these conditions, and in an initial phase ∼50% of the glucose entering the circulation is 
due to glycogenolysis and the reminder (∼5.0 μmol/kg/min) to gluconeogenesis, whose 
the major precursors are lactate, glycerol, glutamine, and alanine. The majority amino 
acids released from skeletal muscle protein are converted to alanine and glutamine for 
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transport through plasma to liver and kidney: alanine being selectively used by liver, 
glutamine being preferentially used in the kidney, while lactate and glycerol used to 
roughly comparable extent by both organs. In the resting post-absorptive state, lactate is 
the major gluconeogenic precursor, accounting for about half of all gluconeogenesis 
(Gerich J, 1993). The proportion owing to gluconeogenesis rapidly increases with the 
duration of fasting, as glycogen stores become depleted; 24 h after the last meal, 
gluconeogenesis accounts for about 70% of all glucose released into the circulation, 
whereas by 48 hours it accounts for over 90%. Although the kidney be able to store 
glycogen, renal cells lack glucose-6-phosphatase to produce glucose. Thus, all the 
glucose released by the kidney is the result of gluconeogenesis. Under normal 
conditions gluconeogenesis in the kidney provides only a small contribution to the total 
circulating glucose; however, during prolonged starvation, the kidney contribution may 
approach that of the liver. Kidney have yet another function in the maintenance of 
glucose homeostasis once that some of the glucose that passes by this organ need to be 
efficiently reabsorbed to prevent losses (Landau et al., 1996; Shrayyef & Landau , 
2010).  
The muscle is not able to release glucose into circulation; however, its ability to 
rapidly increase its glucose uptake is critical decrease plasma glucose after a meal. 
Skeletal muscle has an additional role in maintaining plasma glucose levels: it releases 
free amino acids into circulation to serve as substrates for liver gluconeogenesis. The 
muscle can use glucose, fatty acids, and ketone bodies for energy. The muscle normally 
maintains significant amounts of stored glycogen, small amounts of fatty acids, and 
contains a large pool of protein that can be broken down in emergencies. The resting 
muscle uses fatty acids as its primary energy source; however, glucose (from its own 
glycogen stores and from circulation), is preferred for rapid energy generation (e.g. in 
sudden exercise).  Adipose tissue can give too an important contribution in fed state, 
supplying free fatty acids and glycerol to the circulation to be taken up by the liver as 
substrate to gluconeogenesis.  As was mention glucagon is the main hormone involve in 
this process, however epinephrine has too an important role in this process, for instance 
Glucagon, which increases both glycogenolysis and gluconeogenesis in the liver, 
however, has no effect on the kidney. Epinephrine, which can directly activate hepatic 
glycogenolysis, appears to increase glucose release, predominantly by directly 
stimulating renal gluconeogenesis and, to a lesser extent, by increasing availability of 
gluconeogenic precursors/activators (e.g., glycerol and free fatty acids) (Brant, 1999). .   
4 
 
In the immediate post-feeding state, the glucose is remove manily into skeletal 
muscle and adipose tissue, being this process regulated by insulin. At the same time, 
endogenous glucose production need to be suppressed, what occur by 1) the direct 
action of insulin, delivered via the portal vein, on the liver, and 2) the paracrine effect or 
direct communication within the pancreas between the β- and α-cells, which results in 
glucagon suppression. There are various factors that can affect glucose levels after a 
meal ingestion. These include the time and the degree of physical activity since the last 
meal; the composition and form (liquid vs. solid); rate of gastric emptying; digestion 
within the lumen of the small intestine; absorption into the portal vein; extraction by the 
liver; suppression of endogenous glucose release; and finally the uptake, storage, 
oxidation, and glycolysis of glucose in post-hepatic tissues (Aronoff, 2004). Glucose 
taken up by tissues postprandially can be driven by two ways: immediately stored or 
undergoes glycolysis. Of the glucose undergoing glycolysis, some will be oxidized; the 
remainder will undergo non-oxidative glycolysis leading to the formation of pyruvate, 
lactate, and alanine. These 3-carbon compounds will then be available to undergo 
gluconeogenesis and either be stored in glycogen via the indirect pathway or be released 
into plasma as glucose. In figure 2 is possible analyze the pathways for disposal of a 
mixed meal containing 78 g of glucose. During the 6-h postprandial period, a total of 
∼98 g is available, that is more than the glucose contained in the meal. This occur due 
to persistent endogenous glucose release (∼21 g): Splanchnic tissues initially took up 
∼23 g, and an additional ∼75 g were removed from the systemic circulation. Direct 
glucose storage accounted for ∼32 g and glycolysis ∼66 g (oxidative ∼43 g and non-
oxidative ∼23 g). About 11 g of glucose appeared in plasma as a result of 
gluconeogenesis. This indicates that glycolysis is the main initial postprandial source of 
glucose, accounting for ∼66% of overall disposal. Oxidation and storage each account 
for about 45% (Shrayyef, & Gerich , 2010). 
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Figure 2 - Summary of sites and routes of postprandial glucose disposal (adapted from Woerle et al. 
2003) 
1.1.1 Glucose Utilization 
The majority of glucose is metabolized mainly in six tissues: the brain (45–
60%), skeletal muscle (15–20%), kidney (10–15%), blood cells (5–10%), splanchnic 
organs (3–6%), and adipose tissue (2–4%). Glucose taken up by the brain is completely 
oxidized whereas that taken up by the kidney, blood cells, splanchnic tissues, and 
muscle mainly undergoes glycolysis (Boden, 1997). A summarize of glucose utilization 
in the postabsortive state can be viewed in Figure 3 and Table 1.  
 
 
 
 
 
 
 
 
 
Figure 3 - Glucose utilization and production in the postabsorptive state. The liver and kidney contribute 
approximately 8.0 and2.0 μmol/kg/min, respectively; top, the total release of glucose into the circulation 
(10 μmol/kg/min); the brain, splanchnic tissue, muscle, adipose tissue, and blood cells account for 
approximately 5.0, 2.0, 1.5, 0.5, and 0.5 μmol/kg/min, respectively. (From Gerich, 2010) 
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Table 1- Glucose disposal in the postabsorptive state (Shrayyef, & Gerich , 2010). 
 Rate (µmol/kg/min) % of total 
Overall 10 100 
Oxidation ~7 ~70 
Glycolysis ~3 ~30 
Tissues   
Brain 5 ~50 
Skeletal muscle 2 ~20 
Splanchnic organs 1 ~10 
Kidney 1 ~10 
Adipose Tissue 0.5 ~5 
Blood cells 0.5 ~5 
 
Not all glucose uptake is mediated by the action of insulin - brain, blood cells, 
renal medulla, and splanchnic tissue occurs largely independent of insulin, and plasma 
insulin concentrations are low in the post-absorptive state (<10 μU/ml). Under these 
conditions, amount of glucose removed from the circulation is determined almost 
exclusively by different factors like tissue demands, the mass action effect of the plasma 
glucose concentration per se, and the number and characteristics of the glucose 
transporters in specific tissue rather than by insulin. Insulin may be viewed as playing a 
permissive role, while counter-regulatory hormones that antagonize the action of insulin 
(e.g., cortisol, growth hormone, epinephrine, and thyroid hormones) can be viewed as 
modulating the sensitivity of tissue to the effect of insulin on tissue glucose uptake and 
utilization (Berridje, 2014).  
 
1.1.2 Glucose Uptake 
The uptake of glucose by the cells is a fundamental process mediated by two 
classes of transporter: (1) GLUT family: These transporters facilitated the diffusion of 
glucose, a process that is not energy dependent and that follows Michaelis–Menton 
kinetics. The high-affinity transporters (GLUT 1, 3, 4) have a Michaelis–Menton 
constant (Km) below the normal range of blood glucose concentrations and are capable 
of providing glucose transport under basal conditions for many cells. GLUT3 is 
localized mainly in neurons (lowest Km) whereas GLUT4 mediates insulin stimulated 
glucose uptake by skeletal muscle, heart, and adipose tissues. Insulin and exercise 
promote GLUT3 expression on cell surface. The low-affinity transporters (GLUT2) are 
present on ß-cells and in tissues exposed to large glucose fluxes, such as intestine, liver, 
and kidney. (Bouche et al., 2004) (2) SGLT family: These transporters utilize he 
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electrochemical sodium gradient to transport glucose against concentration gradients 
and are prominent in intestine and kidney. SGLT1 is responsible for the dietary uptake 
of glucose from the small intestine lumen whereas SGLT2 plays a major role in glucose 
reabsorption from proximal renal tubule (Moran et al., 2010). 
 In the last years the number of these glucose, and other sugar, transporters 
identified has increased considerably, mainly the GLUT, with major implications for the 
control of the delivery of glucose to mammalian cells. Among these facilitative 
transporters, GLUT 4 can be highlighted especially because is the major mediator of 
glucose removal from the circulation and a key regulator of whole-body glucose 
homeostasis, being its action stimulated by insulin. The way how insulin stimulates the 
translocation of GLUT 4 for plasma membrane in order to allow the glucose transport to 
inside of cells have been further studied: Insulin binding to its receptor leading to 
receptor autophosphorylation on tyrosine residues and the tyrosine phosphorylation of 
insulin receptor substrates (IRS-1, IRS-2 and IRS-3) by the insulin receptor tyrosine 
kinase. This allows association of IRSs with the regulatory subunit of phosphoinositide 
3-kinase (PI3K) through its SRC homology 2 (SH2) domains. Once activated, the 
catalytic subunit phosphorylates phosphoinositides at the 3¢ position of the inositol ring 
or proteins at serine residues. PI3K activates PtdIns(3,4)P2 / PtdIns(3,4,5)P3-dependent 
kinase 1 (PDK1), which activates PKB/Akt, a serine kinase. PKB in turn deactivates 
glycogen synthase kinase 3 (GSK-3), leading to activation of glycogen synthase and 
thus glycogen synthesis. Activation of PKB also results in the translocation of GLUT-4 
vesicles from their intracellular pool to the plasma membrane, where they allow uptake 
of glucose into the cell. PKB also leads to mTOR-mediated activation of protein 
synthesis by PHAS/elf4 and p70s6k (Fröjdö et al., 2009). 
1.1.3 Insulin 
Insulin, is a small protein composed of two polypeptide chains containing 51 
amino acids. The monomeric structure of insulin consists of the 21 amino acid residue 
“A” chain and 30 amino acid residue “B” chain bound by disulfide linkages. The 
monomer presents three disulfide linkages, including two between the A and B chains 
(A7-B7, A20-B19) and one within the A chain (A7-A11). Insulin regulates glucose 
metabolism by direct and indirect actions. Through binding to its receptors in the liver, 
kidney, muscle, and adipose tissue, insulin activates its signaling pathway which 
involves a complex cascade of protein kinases and regulatory proteins of which IRS-1 
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and IRS-2 are the most important. The primary action of insulin is to stimulate glucose 
clearance. Insulin helps control post-prandial glucose in multiple ways. Initially, insulin 
signals the cells of insulin-sensitive peripheral tissues, promoting mainly the 
translocation of glucose transporters in muscle and adipose tissue; Also, insulin acts on 
the liver to promote glycogenesis; Insulin simultaneously inhibits glucagon secretion 
from pancreatic α-cells, thus signaling the liver to stop producing glucose via 
glycogenolysis and gluconeogenesis (Alarcón et al., 2002). Insulin acts too, promoting 
the inhibition of release of FFA into the circulation due to suppression of the activity of 
hormone-sensitive lipase and a simultaneous increase in their clearance from the 
circulation. Although insulin does not increase glucose transport into liver, it promotes 
glycogen accumulation by inhibiting glucose-6-phosphatase and phosphorylase 
(glycogenolysis enzymes) while stimulating glycogen synthase. All of these actions 
reduce blood glucose. Other actions of insulin include the stimulation of fat synthesis, 
promotion of triglyceride storage in fat cells, promotion of protein synthesis in the liver 
and muscle, and cell growth. Insulin action is carefully regulated in response to 
circulating glucose levels. Insulin is not secreted if the blood glucose concentration is 
lower than 3.3 mmol/l, but is secreted in increasing amounts as glucose concentrations 
increase beyond this threshold. The process of secretion of insulin occurs in two phases: 
an initial rapid release of preformed insulin, followed by a second longer phase that 
imply new insulin synthesis and its release. Long-term release of insulin occurs if 
glucose concentrations remain high. Beside glucose is the most potent stimulus of 
insulin, there are other factors that stimulate insulin secretion. These additional stimuli 
include increased plasma concentrations of some amino acids, especially arginine, 
leucine, and lysine; incretines; and parasympathetic stimulation via the vagus nerve (Fu, 
2013). 
1.1.3.1 Insulin Biosynthesis 
The secreted insulin consists of 51 amino acids with a molecular weight of 5.8 
kDa. However, the insulin gene encodes a 110-amino acid precursor known as 
preproinsulin. As with other secreted proteins, preproinsulin contains a hydrophobic N-
terminal signal peptide, which interacts with cytosolic ribonucleoprotein signal 
recognition particles (SRP). SRP facilitates preproinsulin translocation across the rough 
endoplasmic reticulum (rER) membrane into the lumen. This process occurs via the 
peptide-conducting channel, where the signal peptide from preproinsulin is cleaved by a 
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signal peptidase leading to a production of proinsulin. Proinsulin then undergoes folding 
and formation of three disulfide bonds, a process requiring a diverse range of 
endoplasmic reticulum (ER) chaperone proteins. Subsequent to maturation of the three 
dimensional conformation, the folded proinsulin is transported from the ER to the Golgi 
apparatus where proinsulin enters immature secretary vesicles and is cleaved to yield 
insulin and C-peptide. Insulin and C-peptide are then stored in these secretory granules 
together with islet amyloid polypeptide (IAPP or amylin) and other less abundant β-cell 
secretary products. Although insulin biosynthesis is controlled by multiple factors, 
glucose metabolism is the most important physiological event that stimulates insulin 
gene transcription and mRNA translation. Insulin biosynthesis is regulated both at 
transcriptional and translational levels. Insulin content in β-cells is highly dynamic. 
Insulin accumulates in the presence of nutrients and decreases in response to nutrient 
deprivation. The ability of β-cells to quickly respond to cellular signals is generally due 
to transcriptional regulation (Suckale et al., 2008; Huang &Arvan, 1995). 
 
1.1.3.2 Regulation of insulin secretion 
The signal that leads to insulin secretion is absolutely depend on glucose levels. 
Glucose is internalized by the pancreatic β-cell through the plasma membrane 
transporter GLUT2. Once in the β-cell cytosol, glucose promotes glycolysis to generate 
ATP, NADH and pyruvate. NADH can be shuttled into the mitochondria to produce 
ATP at the electron transport chain. Pyruvate is directly transported into the 
mitochondria, where it is metabolize by the tricarboxylic acid (TCA) cycle to generate 
NADH and FADH equivalents that produce additional ATP. The increase in cytosolic 
ATP levels, leads to a increase in ATP/ADP ratio, a trigger essential to insulin 
exocytosis. The increase in the ATP/ADP ratio causes the closure of ATP-sensitive K+-
channel, which depolarizes the β-cell plasma membrane, with a subsequent opening of 
voltage sensitive L-type Ca2+-channels, and the influx of extracellular Ca2+. The rise 
in intracellular cytosolic Ca2+ concentration acts as a major signal to trigger insulin 
exocytosis (Alarcón et al., 2002). 
 
1.1.3.3 Insulin secretion 
Hyperglycemic clamps and experiments in isolated pancreatic islets have 
demonstrated that glucose induces insulin secretion in a biphasic pattern: an initial 
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component (first phase), which occurring within the first 10 minutes, followed by a 
sustained component (second phase) with a progressively slow increase in insulin 
secretion reaching a plateau in 2-3 hours as seen in rats and humans (Gerich, 2002). 
Loss of first-phase secretion and reduced second-phase secretion are characteristic 
features of type 2 diabetes mellitus (T2D); it is well known that a decrease in the first 
phase of insulin secretion is found in the early stage of T2D and also in impaired 
glucose tolerance (IGT) (Davis et al. 1993). Thus, in order to understand the 
pathogenesis and pathophysiology of these diseases, it is important to clarify the cellular 
and molecular mechanisms responsible for the alterations in the dynamics of insulin 
secretion. Biochemical experiments and capacitance measurement have suggested that 
secretory vesicles generally exist in functionally distinct pools and that sequential 
release of these pools underlies the dynamically separable components of exocytosis 
(Rorsman & Renström, 2003). Pancreatic β cells contain at least two pools of insulin 
secretory granules that differ in release competence: a reserve pool (RP), which 
accounts for the vast majority of granules, and a readily releasable pool (RRP), which 
accounts for the remaining granules (less than 5%). The prevailing hypothesis is that the 
release of RRP granules accounts for the first phase of insulin secretion and that 
mobilization of a subsequent supply of new granules for release by mobilization 
accounts for the second phase. Thus, the initial amount of insulin released upon glucose 
absorption is dependent on the amounts available in storage. Once depleted, a second 
phase of insulin release is initiated. This latter release is prolonged since insulin has to 
be synthesized, processed, and secreted for the duration of the increase of blood 
glucose. Furthermore, beta cells also have to regenerate the stores of insulin initially 
depleted in the fast response phase (Seino et al., 2011). 
  
 
1.1.4 Glucagon 
Glucagon is a key catabolic hormone constitute by 29 amino acids. It is secreted 
from pancreatic α-cells and is particularly important in stimulating glycogenolysis, 
gluconeogenesis, and ketogenesis. Described by Roger Unger in the 1950s, glucagon 
was characterized as opposing the effects of insulin. Glucagon plays a major role in 
sustaining plasma glucose during fasting conditions by stimulating hepatic glucose 
production (Berridge, 2014).  
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Like insulin, glucagon is secreted first into the portal blood and is therefore 
anatomically in a favorable position to regulate hepatic metabolism. Glucagon act 
mainly in the liver, however it appear that have some glycogenolytic action on cardiac 
and skeletal muscle and lipolytic action on adipose tissue, and it promotes the 
breakdown of protein by several tissues. However, these effects on protein tissue 
breakdown appear to be more prominent when tissues are exposed to pharmacological 
concentrations of glucagon. At more physiological concentration, the liver appears to be 
the major target tissue. In many circumstances, the actions of glucagon antagonize those 
of insulin. However unlike the cellular mechanism of action of insulin, the mechanism 
of glucagon action is not so completely understood. 
Hepatic glucose production, which is primarily regulated by glucagon, is 
fundamental to maintain the basal blood glucose levels within a normal range during the 
fasting state. When plasma glucose decrease below the normal range, glucagon 
secretion increases, resulting in hepatic glucose production and return of plasma glucose 
to the normal range. This endogenous source of glucose is not necessary during and 
immediately following a meal, and glucagon secretion is suppressed. When coupled 
with insulin’s direct effect on the liver, glucagon suppression results in a near-total 
suppression of hepatic glucose output. In the diabetic state, there is inadequate 
suppression of postprandial glucagon secretion (hyperglucagonemia) which results in 
elevated hepatic glucose production, contributing determinately to hyperglycemia (Fu, 
2013).  
 
1.1.5 Incretin hormones: GLP-1 AND GIP 
By the late 1960s, Perley and Kipnis and others demonstrated that ingested food 
caused a more potent release of insulin than when glucose was infused intravenously. 
This effect, named “incretin effect,” suggested that exist a signal from the gut that are 
important in the hormonal regulation of glucose clearance. Further, these hormonal 
signals from the proximal gut seemed to help regulate gastric emptying and gut motility. 
Several incretin hormones have been characterized, however the most well studied and 
characterized are GIP and GLP-1. GIP stimulates insulin secretion and regulates fat 
metabolism, but does not inhibit glucagon secretion or gastric emptying. GIP levels are 
normal or slightly elevated in people with type 2 diabetes. 
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GLP-1 is secreted in greater concentrations and is more physiologically relevant 
in humans. GLP-1 also stimulates glucose dependent insulin secretion but is 
significantly reduced post-prandially in people with type 2 diabetes or impaired glucose 
tolerance. In contrast to GIP, GLP-1 inhibits glucagon secretion and slows gastric 
emptying. GLP-1 has many glucoregulatory effects. In the pancreas, GLP-1 stimulates 
insulin secretion in a glucose-dependent manner while inhibiting glucagon secretion 
(become this away a target to therapies). Both GIP and GLP-1 are rapidly inactivated by 
inhibitors of dipeptidyl peptidase 4 (DPP-IV) in vivo (Campbell & Drucker, 2013). 
 
1.2 Diabetes mellitus  
Diabetes mellitus is a group of metabolic diseases characterized by 
hyperglycemia resulting from defects in the main processes involved in regulation of 
insulin levels: insulin secretion, insulin action, and insulin clearance (Al Ali et al., 2013; 
Duckworth, 1998). The prevalence of diabetes is increasing rapidly worldwide and the 
International Diabetes Federation has predicted that by 2030 the number of adults with 
diabetes would have almost doubled worldwide, from 387 million in 2013 to 592 
million (IDF, 2013). Diabetes is also costly to health care systems. People with diabetes 
have more outpatient visits, use more medications, have a higher probability of being 
hospitalized, and are more likely to require emergency and long-term care than people 
without the disease. The global health expenditure on diabetes was 612 billion dollars in 
2014, 11% of total spending on adults (IDF, 2013). Diabetes is now one of the most 
common non-communicable diseases globally. It is the fourth or fifth leading cause of 
death in most high-income countries and there is substantial evidence that it is epidemic 
in many low and middle income countries. Complications from diabetes are resulting in 
increasing disability, reduced life expectancy and enormous health costs for virtually 
every society. Diabetes is certain to be one of the most challenging health problems in 
the 21st century. Thus, it is important channeling health resources, emphasize the 
importance of lifestyle changes, and encourage other measures to counteract trends for 
increasing prevalence of diabetes (Dieren et al.2010). 
The chronic hyperglycemia of diabetes is associated with long-term damage, 
dysfunction, and failure of various organs, especially the eyes, kidneys, nerves, heart, 
and blood vessels. Several pathogenic processes are involved in the development of 
diabetes. These range from autoimmune destruction of the β-cells of the pancreas with 
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consequent insulin deficiency to abnormalities that result in resistance to insulin action. 
In this disease, both carbohydrate, lipid and protein metabolism are impaired, which 
leads to development of specific microvascular complications and of non-specific 
macrovascular disease. The basis of the abnormalities in carbohydrate, fat, and protein 
metabolism in diabetes is the result deficient action of insulin on target tissues. 
Deficient insulin action results from inadequate insulin secretion and/or diminished 
tissue responses to insulin at one or more points in the complex pathways of hormone 
action. Impairment of insulin secretion and defects in insulin action frequently coexist 
in the same patient, and it is often nuclear which abnormality, if either alone, is the 
primary cause of the hyperglycemia. Symptoms of marked hyperglycemia include 
polyuria, polydipsia, weight loss, sometimes with polyphagia, and blurred vision. 
Impairment of growth and susceptibility to certain infections may also accompany 
chronic hyperglycemia. Acute, life-threatening consequences of uncontrolled diabetes 
are hyperglycemia with ketoacidosis or the nonketotic hyperosmolar syndrome. Long-
term complications of diabetes include retinopathy with potential loss of vision; 
nephropathy leading to renal failure; peripheral neuropathy with risk of foot ulcers, 
amputations, and Charcot joints; and autonomic neuropathy causing gastrointestinal, 
genitourinary, and cardiovascular symptoms and sexual dysfunction (Ozougwu, 2013 & 
Valdez et al., 2007). Patients with diabetes have an increased incidence of 
atherosclerotic cardiovascular, peripheral arterial, and cerebrovascular disease. 
Hypertension and abnormalities of lipoprotein metabolism are often found in people 
with diabetes (Lüscher et al, 2003). Insulin clearance is an integral component of insulin 
metabolism, as it regulates the cellular response to the hormone by decreasing insulin 
availability and mediates certain aspects of insulin action. The liver is the primary site 
of insulin clearance. Approximately 80% of endogenous insulin is removed by the liver, 
and the remainder is cleared by the kidneys and muscles. Clearance rates for insulin 
decrease in glucose intolerance, obesity, in particular abdominal obesity, hypertension, 
hepatic cirrhosis, and nonalcoholic fatty liver disease (Lee et al, 2013). Despite its 
potential role in the etiology of diabetes (especially in type 2 diabetes), little is known 
about the factors that are independently associated with decreased of insulin clearance 
in T2D and clearly need further investigation.  
There are a number of different types of diabetes, some of which are more 
prevalent than others. The most common forms of diabetes in the general population are 
type 1 diabetes (T1D) and type 2 diabetes (Ozougwu, 2013). Nevertheless, exists a type 
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of diabetes that is often misdiagnosed as T2D, mainly because share features with T2D 
and with type 1, titled as Latent autoimmune diabetes in adults (LADA) that presents a 
high prevalence (Naik et al., 2009). The common characteristic among these types of 
diabetes are the hyperglycemia, however the causes/pathophysiology are different: i) 
Type 1 diabetes, is caused by lack of insulin secretion by beta cells due to an 
autoimmune reaction to proteins of the islets cells of the pancreas. The pathogenesis of 
selective β-cell destruction within the islet in type 1 diabetes mellitus is difficult to 
follow due to marked heterogeneity of the pancreatic lesions. The autoimmune 
destruction of pancreatic β cells leads to a deficiency of insulin secretion that leads to 
the metabolic derangements associated with type 1 diabetes (Vlad &Timar, 2011); ii) 
Type 2 diabetes, is the more prevalent and is caused by a combination of genetic factors 
related to impaired insulin secretion, insulin resistance, likely insulin clearance, and 
environmental factors such as obesity, overeating, lack of exercise and stress, as well as 
aging. The impairment of pancreatic β cell function notably shows progression overtime 
in type 2 diabetes although aging, obesity, insufficient energy consumption, alcohol 
drinking, smoking, etc are independent risk factors of pathogenesis of type 2 diabetes 
mellitus (Fonseca, 2009); iii) The pathophysiology of LADA is not yet clearly 
understood, but these patients are typically diagnosed after 35 years of age and are often 
misdiagnosed as type 2 Diabetes. Glycemic control is initially achieved with 
sulfonylureas but patients eventually become insulin dependent more rapidly than with 
T2D patients. Although they have a type 2 DM phenotype, patients have circulating 
beta (β) cell autoantibodies, a hallmark of T1D. With regards to its autoimmune basis 
and rapid requirement for insulin, it has been suggested that LADA is a slowly 
progressive form of T1D (Naik et al., 2009). 
The actually numbers of people with diabetes reveals that is necessary 
implement measures in order to decrease this epidemic. Among these possible actions 
the prevention is yet the principal method that can reduce this disease. Thus, it is clear 
that developing strategies to screen and identify high-risk individuals should be an 
important public health goal.  For prevention efforts to be most effective, public health 
programs must recognize the factors involved in diabetes susceptibility.  
Family history of diabetes (FHD) has been recognized as an important risk 
factor of the disease. Family medical history represents valuable genomic information 
because it characterizes the combined interactions between environmental, behavioral, 
and genetic factors. Evidence for strong genetic element diabetes susceptibility is 
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suggested by the high incidence in certain racial/ethnic populations, high concordance 
in monozygotic twins compared with dizygotic twins, and high incidence among first-
degree relatives of persons with diabetes. The complex pathophysiologic nature of 
diabetes supports the idea that multiple biologic and/or chemical pathways are 
implicated in the development and progression of the disease, and numerous genetic 
loci have been investigated in the search for genetic determinants of the disease. The 
use of family history as part of a comprehensive risk assessment for an individual can 
be crucial in the prevention, early detection, and treatment of diabetes. On a population 
level, family history may help tailor health promotion messages for specific population 
groups (Valdez et al., 2007; Annis et al., 2005). 
 
1.2.1 Types of diabetes  
1.2.1.1 Type 1 Diabetes 
 Type 1 diabetes is a chronic inflammatory disease caused by a selective 
destruction of the insulin producing β-cells in the islets of Langerhans, characterized by 
an impaired (or total loss) insulin production. Type 1 diabetes is associated with the 
appearance of humoral and cellular islet autoimmunity, and a defective 
immunoregulation appears to be involved. The exact etiology and pathogenesis of type 
1 diabetes, however, is still unknown. The model of the natural history of type 1 
diabetes suggests stages that commence with a genetic susceptibility, autoimmunity 
without clinical disease, and finally clinical diabetes. Type 1 diabetes is responsible by 
5% to 10% of all cases of diabetes, affecting approximately 20 million people 
worldwide (American Diabetes Association, 2008). Associated risk factors include 
autoimmune, genetic, and environmental factors. Until the present time, known 
solutions to prevent diabetes have not been discovered (Deshpande 2008, 1255).  
Type 1 diabetes affects all age groups, but presents two peaks for onset, the first 
occur in childhood between 5 and 7 yr of age, and the other occur at or near puberty 
(Harjutsalo et al. 2008). Worldwide, the incidence of T1D is increasing, particularly in 
the under-5-years age group (Narendran et al., 2005). However, have the first signs of 
islet autoimmunity very early in life, with the majority by 2 years of age. Children who 
develop autoantibodies within the first 2 years of life are those who most often develop 
multiple islet autoantibodies and progress to type 1 diabetes in childhood. 
Autoantibodies do not exclusively develop before age 2 years, but children who develop 
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autoantibodies later have a slower progression to multiple antibodies and type 1 
diabetes (Kimpimaki et al, 2002). Type 1 diabetes is possible the result of an interplay 
between genetic susceptibility (polygenic) and a triggering environmental agent that 
was thought to provide the fundamental elements for disease formation and, 
additionally, form potential targets for both improved disease prediction and prevention 
autoimmune reaction to proteins of the islets cells of the pancreas (Vlad & Timar, 
2012). Genes clearly determine the likelihood of developing islet autoantibodies and 
progression to multiple islet autoantibodies. It remains controversial, however, if 
progression from multiple islet autoantibodies to type 1 diabetes is influenced by 
genetic factors. It is clear at this point that multiple genes can have predisposing, as well 
as protective effects, resulting in a complex interaction. Overall contribution of genetic 
factors will not explain the etiology of disease alone, since there is a significant 
discordance in monozygotic twins . Other environmental factors are therefore important, 
and many potential candidates were under evaluation; among them dietary factors, 
cow’s milk in young infants, viral infections and psychological stress (Steck, & 
Rewers,,2011).  
Genes for type 1 diabetes provide both susceptibility towards, and protection 
from, the disease. Although many chromosomal loci associated with such activities 
have been located, few true genes have been identified. The genetics of type 1 diabetes 
cannot be classified according to a specific model of dominant, recessive, or 
intermediate inheritance of a specific set of genes. The most important genes are located 
within the major histocompatibility complex (MHC) HLA class II region on 
chromosome 6p21, accounting for about 45% of genetic susceptibility for the disease. 
The function of these genes in terms of an immune response is well known (ie, 
presentation of antigenic peptides to T lymphocytes), yet their specific contribution to 
the pathogenesis of type 1 diabetes remains unclear (Steck, & Rewers,,2011). 
 
 
1.2.1.2 Pathophysiology of T1D 
 
T1D as autoimmune disease, the end stage culminating in destruction of the 
pancreatic b cells, characterized histologically by insulitis (i.e., islet cell inflammation) 
and associated β-cell damage. It remains unclear why the autoimmunity in T1D is 
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specific to the insulin-producing β cells. Beyond this, the specific mechanisms 
responsible for inducing the autoimmunity in T1D also have yet to be elucidated. The 
inflammatory lesion within islets of those with T1D is typically characterized by a 
decrease (or absence) of insulin-producing β-cells along with a pancreatic islet cell 
infiltrate composed of T-lymphocytes, B-lymphocytes, macrophages, and lesser 
numbers of other cells representing the immune response. It is import refer that the 
study of this process is not easy mainly because pancreatic biopsies in humans is not 
considered, in most of the cases an ethical procedure. Therefore, the majority of analysis 
of this process is realized in animal models or in autopsies. Autoimmunity in T1D has 
typically been identified by the presence of autoantibodies to islet and/or b-cell 
antigens, which in addition to their presence at the time of diagnosis, can often be 
detected long before the disease becomes clinically evident (Atkinson, 2012). Among a 
list of T1D-associated autoantibodies that actually has more than two dozen members 
are islet cell autoantibodies (ICAs), autoantibodies to glutamic acid decarboxylase 
(GADAs), insulin autoantibodie (IAAs), and autoantibodies to transmembrane tyrosine 
phosphatase (IA2As), as well as those against the ZnT8 molecule (ZnT8As). Although 
these are the five most prevalent and best characterized, the potential for other 
autoantibody/ autoantigen combinations remains. Other point that yet still controversial 
is whether such antibodies play a pathogenic role. For decades, the predominant dogma 
was that autoantibodies possessed no known etiological role in the disease (Zhang et al. 
2008). 
 Over the past three decades, the ability to understand the natural history of T1D 
has improved dramatically through the combined use of genetic, autoantibody, and 
metabolic markers of the disease. In the mid-1980s, a model was develop integrating 
these three features. This model for the natural history of T1D suggests that genetically 
susceptible individuals are exposed to an environmental trigger, which induces b-cell 
autoimmunity. This process, initiate by the development of islet reactive autoantibodies, 
portends the development of activated autoreactive T cells capable of destroying b cells, 
resulting in a progressive and predicable loss in insulin secretory function. According to 
this model, the symptoms of T1D do not present until 80%–90% of the β cells have 
been destroyed, and there is a marked gap between the onset of autoimmunity and the 
onset of diabetes (Atkinson, 2005). This model has been a guide line for several years, 
but some aspects of the classical model have been modified to update knowledge gains 
(Fig. 1.3) (Atkinson, 2012). Among these updates, can be highlighted for instance that 
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are data to suggest that pancreatic β-cells may persist in some individuals with T1D for 
an extended period of time (i.e., never reaching zero in many T1D patients) (Meier et al. 
2005). In addition, the degree of b-cell destruction required for symptomatic onset has 
been also debated, with recent studies suggesting that 40%–50% b-cell viability may be 
present at the onset of hyperglycemia. This may explain why, despite persistent 
autoimmunity, insulin secretory function can remain stable for long periods of time in 
persons with T1D. The inflammation and a decrease of β-cell mass leads then to a loss 
of first-phase insulin response, followed by a period of glucose intolerance and a period 
of clinically “silent” diabetes (Sosenko et al. 2010). The “slope” reflective of b-cell loss 
in the pre-diabetic that leads to diabetes period has also recently been subject to 
considerable debate, with some proposing that the disorder may see its symptomatic 
onset only following a period of relapsing/remitting like autoimmunity (Fig 4). Thus, 
this means that the onset of clinical disease represents the end stage of β-cell destruction 
(Atkinson, 2012). 
In addition to the loss of insulin secretion, the function of pancreatic α-cells is 
also abnormal and there is excessive secretion of glucagons in T1D patients. The 
resultant inappropriately elevated glucagons levels exacerbate the metabolic defects due 
to insulin deficiency. The most pronounced example of this metabolic disruption is that 
patients with T1D rapidly develop diabetic ketoacidosis in the absence of insulin 
administration. Deficiency in insulin leads to uncontrolled lipolysis and elevated levels 
of free fatty acids in the plasma, which suppresses glucose metabolism in peripheral 
tissues such as skeletal muscle. This impairs glucose utilization and insulin deficiency 
also decreases the expression of a number of genes necessary for target tissues to 
respond normally to insulin such as glucokinase in liver and the GLUT 4 class of 
glucose transporters in adipose tissue (Ozougwu et al., 2013).  
 Thus, the combination of increased hepatic glucose production and reduced 
peripheral tissues metabolism leads to elevated plasma glucose levels. When the 
capacity of the kidneys to absorb glucose is suppressed, glucosuria occurs. Glucose is 
an osmotic diuretic and an increase in renal loss of glucose is accompanied by loss of 
water and electrolyte. The result of the loss of water (and overall volume) leads to 
polydipsia. The negative caloric balance, which results from the glucosuria and tissue 
catabolism leads to an increase in appetite and food intake that is polyphagia (Ozougwu 
et al., 2013). 
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Other effect that is noted in T1D is the loss of weight. In uncontrolled T1D there 
is a rapid mobilization of triglycerides leading to increased levels of plasma free fatty 
acids. The free fatty acids are taken up by numerous tissues (except the brain) and 
metabolized to provide energy. In the absence of insulin, malonyl COA levels fall, and 
transport of fatty acyl-COA into the mitochondria increases. Mitochondrial oxidation of 
fatty acids generates acetyl COA that can be further oxidized in the TCA cycle. 
However, in hepatocytes the majority of the acetyl COA is not oxidized by the TCA 
cycle but is metabolized into the ketone bodies (acetoacetate and b-hydroxybutyrate). 
These ketone bodies are used for energy production by the brain, heart and skeletal 
muscle. In T1D, the increased availability of free fatty acids and ketone bodies 
exacerbates the reduced utilization of glucose, furthering the ensuing hyperglycemia. 
Production of ketone bodies in excess of the body’s ability to utilize them leads to 
ketoacidosis (Achenbach et al., 2005).  
Beyond all this information that is already known about the disease, there are 
features that need to be clarify: identification of genes controlling disease susceptibility, 
improved understanding of autoimmunity/mechanisms underlying loss of immune 
regulation, and further identification of environmental agents influencing the disease are 
all examples of information needed to impact efforts toward the goal of disease 
prevention; each is discussed below. Likewise, understanding events (e.g., rate of C-
peptide loss, the presence of residual b cells, etc.) following symptomatic onset are also 
of importance because many ongoing efforts are actively seeking to reverse the disorder 
in those previously diagnosed with the disease. Other important factor that clearly needs 
to be clarified is the importance of family history of diabetes as risk factor for T1D. 
 
 
 
 
 
 
  
  
Figure 4 - Model of the pathogenesis and natural history of type 1 diabetes. The modern model expands 
and updates the traditional model by inclusion of information gained through an improved understanding 
of the roles for genetics, immunology, and environment in the natural history of T1D. FPIR – First phase 
of Insulin release; IVGTT - intravenous glucose tolerance test.  The time it takes to the onset of T1D is 
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variable, being shorter when T1D appear in child and longer when T1D only is diagnosed on adult phase. 
(From Atkinson, 2012).  
 
1.2.2.1 LADA 
 Latent autoimmune diabetes of the adult (LADA) is a common form of diabetes 
that presents several features of both type 1 and type 2 diabetes. Lada can be 
categorized as an autoimmune diabetes form, being the pathology characterized by the 
presence of diabetes-associated autoantibodies against β-cell. Unlike type 1 diabetes, 
these patients are normally detected in adulthood and are non-insulin requiring at time 
of diagnosis. Regarding to metabolic dysregulations involved, LADA presents 
similarity with type 2 diabetes (insulin resistance), demonstrating the high heterogeneity 
of this pathology (Carlsson et al., 2007).  
 The term latent autoimmune diabetes in adults (LADA) was introduced by 
Zimmet (Zimmet, 1995). to define adult diabetic patients initially non–insulin-requiring 
but with immune markers of type 1 diabetes that, in a number of cases, progress to 
insulin dependency. First, this type of diabetes was called slow-progressing type 1 
diabetes, but a slow progression of b-cell destruction can be considered as only one of 
the possible explanations. Several terms like 1.5 diabetes, latent type 1 diabetes, or 
youth onset diabetes of maturity have been suggested to classify the pathology instead 
LADA. However, the term autoimmune diabetes not requiring insulin at diagnosis (or 
LADA) seems to be the more appropriate because the concept of latency indicates 
patients of adult age who do not require insulin at least for 6 months after diagnosis and 
who possess immunological and genetic features typical of type 1 diabetes (Nambam et 
al., 2010). 
 As expected all these characteristics leads to an often misdiagnosed of type 
diabetes presented, it is not easily discernible signs and symptoms. Lada patients 
typically have some features that distinguishes it from T1D and T2D (Table 2), but a 
diagnosis of LADA is still a challenge. This can have significantly influence in the 
epidemiologic numbers but mainly in the type of the therapy to apply. Due to the latent 
nature of the disease, LADA patients are often diagnosed as T2D and started on oral 
hypoglycemic. However, glycemic control deteriorates after a few months/years of 
therapy and by the time insulin therapy is started, the disease often progresses to the 
morbid stage which could have been delayed with timely initiation of insulin therapy 
dependency. The progression to insulin dependence in LADA patients is believed to be 
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more rapid than in type 2 diabetes subjects. The usual clinical features of these patients 
include weight loss, ketosis proneness, unstable blood glucose levels, and an extremely 
diminished C-peptide reserve (Naik et al., 2009).   
 Table 2- Diagnostic features of type 2, LADA and type 1 diabetes mellitus (From Ola et al., 
2006). 
Features Type 1 Diabetes LADA Type 2 Diabetes 
Metabolic syndrome Present Reduced frequency Absent 
Ketoacidosis  Absent Usually absent Present 
Cardiovascular 
Complications 
Present Present Present 
Microvascular 
Complications 
Present Present Present 
Islet cell autoantibodies Negative Positive Positive 
Treatment with insulin Required late in course 
of disease 
Required at least 6 
months after diagnosis 
Required at diagnosis 
 
 As T1D, the epidemiology of LADA is influenced by geography, genetic 
susceptibility, environmental factors, gender and age at diagnosis, but a fact already 
related that can lead to significant bias of results is the misdiagnosed. The onset of 
diabetes in adulthood result in a high percentage of patients that are misdiagnosed with 
type 2 patients and are not submitted to an autoantibody test – essentially to a diagnosis 
of LADA. Thus, it´s absolutely important determine who should be subjected to this 
type of test. Many clinicians only asks for the antibody assay if exists a suspicion of 
LADA based on BMI (< 25kg/m
2
). Obese, adult onset diabetics are often categorized as 
type 2 DM and not tested for LADA while adults with normal BMI are potentially 
suspected for LADA and hence tested.  Nevertheless, the prevalence of LADA has been 
estimated in a number of studies worldwide. A wide variation has been described, partly 
depending on the markers chosen to define the condition but also on the characteristics 
of the patients (e.g., newly diagnosed or previously diagnosed), but these studies have 
identified a prevalence of 10–20% of non–insulin requiring diabetic patients with ICA 
and GAD antibodies, therefore with LADA (Nambam et al., 2010; Pozzilli & Di Mario, 
2001).  
  
1.2.2.2 Pathophysiology of LADA 
 As described below, LADA is defined as a latent form of T1D. There are several 
evidences that can explain the age of onset of this autoimmune diabetes in adults. Some 
studies suggests that in LADA, the typical HLA genetic predisposition to type 1 
diabetes is less marked than in patients diagnosed in younger age. Others explanation is 
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that the interaction between environmental and genetic features is less acute in LADA 
patients. T-cell “insulitis” is also observed in LADA patients like in T1D, however the 
immune tolerance to b-cell antigens is probably higher in LADA, which can contribute 
to protect these patients from extensive T-cell destruction of b-cells (Poudel, 2012).   
 The process that leads to b-cell destruction varies according to the age when 
hyperglycemia is diagnosed, as indicated by the residual β-cell function found at age of 
diagnosis. It is possible that in the childhood, a linear and rapid progression toward 
exhaustion of the b-cell function occur, while in the adolescent, a longer followed by an 
acute precipitating factor (maybe viral) may be more common, based on available data. 
In LADA, it is believed that numerous events can hit the b-cells in genetically 
susceptible subjects, promoting the decline of b-cell function. This could be one of the 
possible explanations of pathogenic mechanisms. Therefore, the age at diagnosis is 
influenced by the amount of b-cell remainder, which is clearly more elevated in patients 
with LADA unlike the adolescent or the very young with TID.  
 Although are both autoimmune diseases there are differences in antibodies 
between LADA and type 1 diabetes. Many researchers have demonstrated that anti-
GAD and ICA are much more common than IAA, IA-2A, and ZnT8 antibodies in 
LADA patients vs. type 1 patients (Hosszúfalusi et al., 2003; Cervin et al., 2008). These 
autoantibodies can distinguish between acute-onset type 1 diabetes and LADA because 
GAD antibodies and ICA indicate slow disease progression, whereas the presence of 
IA-2 antibodies is associated with an acute-onset clinical phenotype. The presence and 
quantity of single or a multiple antibodies in patients are also factors that clearly 
influence the progression of this disease. Presence of multiple autoantibodies and/or a 
high titer of anti-GAD autoantibodies, compared with single and low-titer autoantibody, 
was associated with an earlier age at onset, lower fasting C-peptide values, and a higher 
likelihood for future insulin requirement (Van Deutekom et al., 2008). It also has been 
observed that first degree relatives of patients that present multiple autoantibodies have 
a higher risk of developing T1D. The presence of circulating autoantibodies as well as 
the early requirement of insulin LADA patients has led to workers suggesting that 
LADA is a spectrum of type I DM with a much slower progression. The slower 
progression has been attributed to a more restricted antigen spreading in LADA than in 
type I DM leading to a more aggressive disease in the latter (Nambam et al., 2012).   
 Cell dysfunction in LADA has been reported to be intermediate between type 1 
and type 2 diabetes. LADA subjects appear to have a faster decline in C-peptide levels 
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compared with people with type 2 diabetes. In comparison, a greater rate of decline in 
C-peptide has been reported in adult type 1 diabetes compared with LADA. Other 
investigators have also observed differences in insulin secretion between type 1 
diabetes, LADA, and type 2 diabetes (Naik et al., 2009). A study revealed that the level 
of insulin secretion in LADA was intermediate between type 1 and type 2 diabetes and 
that fasting and stimulated C-peptide were reduced in LADA compared with type 2 
diabetes (Gottsater et al. 1993). 
 Other feature that has been studied over the years is the role of insulin resistance 
and obesity; Because LADA subjects span the spectrum from lean to obese, differences 
in insulin sensitivity could be an important variable in their physiology. According to 
several studies the degree of insulin resistance in LADA has been reported to be less 
than in type 2 diabetes and comparable to type 1 diabetes. However how insulin 
resistance can contribute to the pathophysiology of LADA is a question that is yet not 
solved.  A recent study in adult European diabetes patients has shown that the 
prevalence of metabolic syndrome is significantly higher in type 2 diabetic patients than 
in patients with LADA or adults with type 1 diabetes; it was further shown that 
metabolic syndrome is not more prevalent in patients with autoimmune diabetes than in 
control subjects, and metabolic syndrome is not a characteristic of autoimmune diabetes 
(Hawa et al., 2009).  
  
1.2.3.1 Type 2 Diabetes 
 Type 2 diabetes is the most common form of diabetes. The World Health 
Organization (WHO) estimates that 90 percent of people with diabetes suffer from type 
2 diabetes (~ 348 million). T2D is non-autoimmune, unlike LADA and T1D, and is 
characterized by hyperglycemia, insulin resistance, relative insulin deficiency and 
impaired insulin clearance. T2D results from an interaction between genetic, 
environmental and behavioral risk factors, like obesity, over eating, lack of exercise, 
and stress and aging. It is typically a multifactorial disease involving multiple genes and 
environmental factors to varying extents (Al li, et al., 2013).  
 T2D is now an epidemic disease and the number of people with this disease is 
increasing in every country, with 80% of people with DM living in low and middle 
income countries. It is estimated that 439 million people would have T2D by the year 
2030. The incidence of T2D varies substantially from one geographical region to the 
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other as a result of environmental and lifestyle risk factors (International Diabetes 
Federation, 2013). The population of Portugal has not been spared from the global surge 
in T2D as vividly described by the first study of diabetes prevalence in Portugal 
conducted by the Portuguese Diabetes Association (APDP). The overall diabetes 
incidence is 11.7%, of which 5.1% were newly diagnosed during the study. The 
prevalence of impaired fasting glucose and/or impaired glucose tolerance (pre-diabetes) 
was 23.3% (Gardete-Correia et al., 2010). 
 Although all the great progressions that have been done in the last years, the 
current knowledge about the etiology of diabetes and pre-diabetes is insufficient to 
decrease the alarming numbers observed all over the world. The increase in type 2 
diabetes is related to lifestyle changes that have resulted in overweight, obesity, and 
decreased physical activity levels. A westernised lifestyle, which involves a high-energy 
diet and reduced physical activity, is certainly linked to the pandemics of obesity and 
type 2 diabetes. Rates of overweight, obesity, and diabetes rise suddenly in populations 
that move from traditional rural to urban environments. Dietary changes are typically 
from unprocessed, low-energy, high-fiber foods to processed, energy-dense foods 
characterized by high sugar and fat contents. Micronutrient imbalances, including 
deficiency in concentrations of vitamin D, vitamin B12 in individuals replete with folic 
acid, and increased body iron stores have been implicated in the pathogenesis of type 2 
diabetes (Nolan et al.,2011). Evidence also suggests that exposure to some synthetic 
organic pollutants (eg, pesticides) affects endocrine cells and increases the risk of 
developing type 2 diabetes (Casals-Casas et al., 2011). Thus, all these environmental 
and behavioral features, along with genetic predisposition, increase insulin resistance, 
which, in concert with progressive β-cell failure, results in rising glycemia in the 
nondiabetic range. In addition to the risk for diabetes, insulin resistance and impaired 
insulin secretion and clearance are accompanied by a host of major cardiovascular 
disease (CVD) risk factors including hypertension and dyslipidemia. Further reduction 
in insulin secretion over time results in increasing glycemia and the development of 
diabetes. The transition from the early metabolic abnormalities that precede diabetes, 
impaired fasting glucose (IFG) and impaired glucose tolerance (IGT), to diabetes may 
take many years; however, current estimates indicate that most individuals (perhaps up 
to 70%) with these pre-diabetic states eventually develop diabetes (Tabák et al., 2014).  
 Although the main metabolic defects of type 2 diabetes are present to some 
degree in most patients, this disorder is highly heterogeneous. Many different 
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susceptibility genes have been identified that interact with environmental factors, during 
gestation, early childhood, and later in life. Nevertheless the exact significance of 
individual genes for disease onset is still only partly resolved although previous twin 
studies applying quantitative genetic models suggested a substantial genetic component 
behind this disease. A hereditary component is suggested from a number of studies that 
assessed the influence of a family history of diabetes on risk of type 2 diabetes; most 
studies report a two- to six fold increased relative risk of type 2 diabetes and the 
associations appear to be independent of lifestyle factors, highlighting the importance of 
FHD (Wikner et al., 2013).   
 It is believed that the decline of β-cell function is the main factor that contributes 
to disease progression, being therefore determinant the acute insulin response to define   
the glucose tolerance status over time. Among Pima Indians, over a mean of 5.1 years, 
progressors (from normal glucose tolerance to IGT and then diabetes) differed 
significantly from non-progressors in their acute insulin response. Acute insulin 
response decreased by 27% during the transition from normal to impaired glucose 
tolerance and by 51% during the transition from impaired glucose tolerance to diabetes, 
and in nonprogressors, it actually increased by 30% (Weyer et al., 2001). Longitudinal 
changes in β -cell function were assessed over 5 years. Again, the main determinant of 
glucose tolerance status during follow-up was the change in acute insulin response. 
Normal glucose tolerance was maintained by a compensatory increase in insulin 
secretion, whereas failure to increase insulin secretion led to impaired glucose tolerance, 
and a decrease in insulin secretion led to overt diabetes. Thus, the progressive decrease 
in β-cell insulin secretion, particularly the first phase insulin secretion that occurs 
acutely after an increase in glycaemia, is likely the most critical functional β -cell defect 
in the development of type 2 diabetes (Festa et al.,2006). 
  
1.2.3.2 Prediabetes 
 
 Prediabetes is an intermediate stage in between normal glucose regulation and 
diabetes and can be characterized by either impaired fasting glucose and/or impaired 
glucose tolerance. IFG and IGT subjects should not be viewed as clinical entities in their 
own right but rather risk factors for diabetes as well as cardiovascular disease. The term 
prediabetes itself has been further discuss on the basis that many people with 
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prediabetes do not progress to diabetes, the term may imply that no intervention is 
needed as no disease is present, and  diabetes risk does not necessarily differ between 
people with prediabetes and those with a combination of other diabetes risk factors. 
Indeed, the WHO used the term ‘Intermediate Hyperglycemia’ and an International 
Expert Committee convened by the ADA the ‘High Risk State of Developing Diabetes’ 
rather than ‘prediabetes” (Tabák et al., 2014). However the most conventional way to 
refer this intermediate hyperglycemic state is prediabetes, and this way will be used in 
the present work. The transition from the early metabolic anomalies that precede 
prediabetes to diabetes may take many years; however, recent estimates indicate that 
most individuals (~ 70%) with these prediabetic states eventually develop diabetes. 
During the prediabetic state, the risk of develop CVD event is modestly increased. 
However with the progression to diabetes, there is a large increase in risk for CVD, as 
well as for long-term complications affecting the eyes, kidneys, and nervous system 
(Nathan et al., 2007; Levitan et al., 2004). The complications associated with diabetes, 
which are the cause of major morbidity and mortality, are related to its duration, chronic 
level of glycaemia, and other risk factors. As expected,   several evidences show that the 
risk for DM in prediabetic subjects is much higher compared with those with normal 
glucose tolerance (NGT). When several prospective epidemiological studies were 
analyzed, the incidence of T2D in isolated IFG and IGT subjects was estimated at 4 to 
6% per year, and this value was significantly higher than NGT subjects (<0.5% per 
year). In the subjects who were diagnosed with IFG and IGT in combination, the annual 
percentage for the risk of developing T2D increased by 10% (Rhee & Woo, 2011).  
However several studies have demonstrated too that after lifestyle and drug-based 
interventions, the cases of prediabetes can be reverted to normal glucose tolerance. In a 
population-based observational study of the natural history of diabetes in England, 
55%–80% of the participants with IFG at the initial phase, had achieve normal fasting 
glucose after a 10-year follow-up (Forouhi et. Al, 2012).  
 IFG is currently defined by an elevated fasting plasma glucose (FPG) 
concentration (≥ 100 and < 126 mg/dl) (29). IGT is defined by an elevated 2-h plasma 
glucose concentration (≥140 and < 200 mg/dl) after a 75-g glucose load on the oral 
glucose tolerance test (OGTT) in the presence of an FPG concentration <126 mg/dl. 
With the definitions above, is detected an overlap between these two groups. To study 
the separate characteristics of prediabetic states, classifications of isolated IFG and 
isolated IGT that are mutually exclusive have been created (isolated IFG = FPG of 100–
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125 mg/dl with the 2-h value <140 mg/dl; isolated IGT = 2-h value of 140– 199 mg/dl 
with the fasting level < 100 mg/dl). The combined characteristics of IFG and IGT have 
been studied by identifying populations that accomplish both criteria (FPG = 100 –125 
mg/dl and 2-h value = 140–199 mg/dl). Thus, normal glucose tolerance (NGT) is 
defined as FPG < 100 mg/dl and 2-h plasma glucose < 140 mg/dl (Table 3) (American 
Diabetes Association, 2010). 
 
Table 3 - Classification of glucose tolerance states (from American Diabetes Association, 2010)  
State FPG 2-H plasma glucose in OGTT 
(mg/dl)* 
IFG 100 - 125 < 200 
Isolated IFG 100 - 125 < 140 
IGT  < 126 140 – 199 
Isolated IGT < 100 140 – 199  
Combined IFG/IGT 100 – 125 140 – 199  
NGT < 100 < 140  
T2D ≥ 126 ≥ 200 
*Standard 75 – g OGTT 
 According to the IDF Diabetes Atlas, the number of cases of IGT in 2010, 
worldwide is estimated to be approximately 340 million. By 2030, the global prevalence 
of IGT is estimated to reach 8.4%, which will be approximately 462 million people 
(IDF, 2013). The highest prevalence of IGT in the world is in North America, with 
10.4%. For Europe and the Middle East, the values are 8.9% and 8.2%, respectively, 
which is also relatively high versus other parts of the world. In Southeast Asia the 
prevalence is 6.2% and in the Western Pacific Region is 7.7%. Generally, the 
prevalence of IGT is known to be higher than that of IFG; however, these data were 
mostly based on the previous ADA/WHO criteria. According to the new ADA criteria, 
when the IFG cut-off value is adjusted from 110mg/dL to 100 mg/dL, IFG prevalence 
increases dramatically. In this case, the increase in IFG prevalence is greater than that of 
IGT (Rhee & Woo, 2011). For example, by changing the IFG diagnostic criteria, the 
Danish IFG prevalence increased from 11.8% to 37.6% (Glumer et al., 2003). Further, 
by changing the diagnostic criteria in DETECT-2 study subjects, IFG prevalence 
increased from 12.7% to 28.7% in Chinese subjects, from 11.0% to 38.6% in Asian 
Indians, from 16.3% to 45.7% in French subjects, and from 12.1% to 32.0% in the 
Unites States (Borch-Johnsen et al., 2003).  
 Both IFG and IGT have a heterogeneous pathogenesis, and this reason may 
contribute to different rates of progression to diabetes. Several studies tried to quantify 
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the risk of prediabetics to develop diabetes and others diseases associated in comparison 
with normal glucose tolerance subjects. Individuals with both IFG and IGT have 
approximately double the rate of developing diabetes compared with individuals with 
just one of them. Numerous longitudinal studies indicate that both IFG and IGT are 
associated with a modest increase in the hazard ratio (~1.1–1.4) for CVD, with IGT 
being a slightly stronger risk predictor. Many cardiovascular risk factors (e.g., low HDL 
cholesterol, hypertension, and elevated triglycerides) are prevalent in IFG and IGT, but 
it is unclear whether they occur more frequently in one state than the other. However, 
after adjustment for known cardiovascular risk factors, both IFG and IGT remain as 
independent, albeit weak, risk factors for CVD in some studies but not in others. Even 
so, it is unclear whether the CVD risk associated with IFG or IGT can be attributed to 
the development of diabetes during follow-up or whether these states per se convey 
such risk (Nathan et al., 2007). 
 1.2.3.3 The pathophysiology of prediabetes 
 Fasting plasma glucose levels are determined by endogenous glucose production 
(EGP) that is mostly dependent on the liver. The product of EGP and fasting insulin is 
used as a marker of hepatic insulin resistance and it shows a relatively strong 
relationship with fasting glycaemia.  
 During absorption of a glucose-containing meal, changes in glucose levels are 
determined by intestinal absorption, suppression of EGP and by total body glucose 
clearance. After glucose ingestion, EGP is markedly suppressed in people with NGT, 
while this suppression is less pronounced in prediabetes and even less in diabetes. In 
type 2 diabetes, total body glucose clearance is also decreased and 85–90% of this 
impairment is related to muscle insulin resistance. If the secretion of insulin by β-cells 
were able to compensate for insulin resistance perfectly, no observable changes in 
glucose levels would occur. Therefore, this apparently suggests that some β-cell 
dysfunction is already present in the prediabetic phase (Tabák et al, 2009). In several 
studies that used different measures of β-cell function, was reported severely abnormal 
(up to 80% decreased) insulin secretion in prediabetic people (Abdul-Ghani et al., 2006; 
Ferrannini et al., 2007). This observation is supported by autopsies reporting a 50% 
decrease in β-cell volume among those with glucose values within the IFG range (Butler 
et al., 2003). The epidemiologic differences between IFG and IGT suggest that different 
pathophysiologic mechanisms are involved, contributing to these disturbances in 
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maintenance of glucose homeostasis. These differences can be observed, for instance, 
during an OGTT with glucose dose of 75-g, where the subjects with different states of 
glucose tolerance present different response curves. People with isolated IGT have, by 
definition, FPG levels that are similar to those with NGT. However, following glucose 
ingestion the plasma glucose concentration rises excessively at all-time points and 
remains elevated (by definition 140–199 mg/dl) after 120 min (Fig. 5). On the other 
hand, in isolated IFG, the FPG is higher (by definition 100 –125 mg/dl) than in NGT 
and isolated IGT, and the plasma glucose concentrations at 30–60 min in the OGTT are 
greater than in both NGT and isolated IGT. Thereafter, the plasma glucose 
concentration in IFG declines to near-baseline values at 120 min. These two very 
distinct oral glucose tolerance curves reflect different pathophysiologic disturbances in 
glucose homeostasis in isolated IFG and isolated IGT. The plasma glucose curves in 
people with both IFG and IGT reflect the characteristics of both (Nathan et al., 2007). 
 Although both isolated IFG and isolated IGT are considered insulin-resistant 
states, are detected differences in their site of insulin resistance. People with isolated 
IFG predominantly have hepatic insulin resistance and normal muscle insulin 
sensitivity, whereas individuals with isolated IGT have normal to slightly reduced 
hepatic insulin sensitivity and moderate to severe muscle insulin resistance. As 
expected, subjects with both IFG and IGT have both muscle and hepatic insulin 
resistance. The pattern of insulin secretion also is different between IFG and IGT. 
People with isolated IFG have a decrease in first-phase (0–10 min) of insulin secretion 
in response to an intravenous glucose and a reduced early phase (first 30 min) insulin 
response to oral glucose. However, the late-phase (60–120min) plasma insulin response 
during the OGTT is normal in isolated IFG. Isolated IGT also has a defect in early-
phase insulin secretion in response to an oral glucose load and in addition has a severe 
deficit in late phase insulin secretion. The combination of hepatic insulin resistance and 
defective insulin secretion in isolated IFG results in excessive fasting hepatic glucose 
production accounting for fasting hyperglycemia. The impairment in early insulin 
response in combination with hepatic insulin resistance results in the excessive early 
rise of plasma glucose in the 1st hour of the OGTT. However, the preservation of late 
insulin secretion combined with normal muscle insulin sensitivity allows glucose levels 
to return to the preload value in isolated IFG. In contrast, in isolated IGT the defective 
late insulin secretion, combined with muscle and hepatic insulin resistance, results in 
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prolonged hyperglycemia after a glucose load (Nathan et al., 2007; Tabák et al., 2012; 
Rhee & Woo, 2011) . 
 
 
 
Figure 5 -  Plasma glucose concentration during an OGTT performed in subjects with IFG, IGT, NGT, or 
combined IFG/IGT (CGI) (From Abdul-Ghani et al., 2006) 
 
 1.2.3.4 Pathophysiology of T2D 
 T2D is characterized by insulin insensitivity as a result of insulin resistance, 
declining insulin production, impaired insulin clearance pancreatic beta-cell failure. 
This leads to a decrease in glucose transport into the liver, muscle cells, and fat cells. 
Regarding to insulin clearance, this mechanism over the years has been viewed as a 
compensatory mechanism, however recently this concept was changed being this 
process linked to T2D pathology - some studies suggesting that increased insulin 
resistance is associated with reduced insulin clearance. The involvement of impaired alpha-
cell function has recently been too recognized in the pathophysiology of T2D. As a 
result of this dysfunction, glucagon and hepatic glucose levels that rise during fasting 
are not suppressed with a meal.  Given inadequate levels of insulin and increased insulin 
resistance, hyperglycemia results (Wikner et al, 2013; Lee et al., 2013).  
 The role of incretins in T2D must be considered once these represent a possible 
target to therapies. In healthy people, up to 70% of post‑glucose insulin secretion is 
mediated by incretins. However, in T2D patients, the insulin response to oral glucose is 
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blunted in comparison to non‑diabetic control subjects, suggesting impairment of the 
incretin effect. In T2D patients during hyperglycemic clamp studies, infusion of GLP‑1, 
but not GIP, stimulates insulin secretion, establishing that the insulinotropic effect of 
GLP‑1 is relatively well‑preserved in T2D, despite possibly lower levels, when 
compared to non‑diabetic subjects. On the other hand, GIP levels are essentially normal 
in T2D but GIP‑stimulated second‑phase insulin secretion is markedly diminished 
(although it has recently been reported that reversal of poor glycemic control in T2D 
improves the insulin response to both GIP and GLP‑1). However, like GIP, GLP-1 is 
rapidly inactivated by DPP-IV in vivo. Thus, the therapies involving incretines has been 
mainly focus on inhibitors of DPP-IV, with special attention to GLP-1 due to its effect 
on glucagon (Nolan et al., 2011; Campbell & Drucker, 2013).  
 Pancreatic β-cells normally respond to insulin resistance by increasing their 
output of insulin to meet the needs of tissues. Development of type 2 diabetes 
essentially results from a failure of the β-cell to adequately compensate for insulin 
resistance. The β-cell dysfunction progresses over time and is well advanced by the time 
that glucose level is in the diabetic range and continues to worsen after diabetes 
develops. Many obese individuals, who tend to have insulin resistance, progress to 
diabetes. However this doesn´t occur in all, with β-cells remaining to function 
adequately and this away being able to maintain glucose homeostasis and compensate 
for increasing insulin resistance with increasing insulin secretion. This mechanism can 
occur through increased insulin secretion from each β-cell and/or an increase in the β-
cell mass. Some individuals have a reduced insulin secretion or reduced β -cell mass but 
normal glucose levels; they have sufficient insulin sensitivity to ensure adequate insulin 
secretion. In insulin-resistant subjects or subjects with type 2 diabetes, there is 
inadequate insulin secretion from each β-cell or an inadequate β-cell mass for the levels 
of prevailing insulin sensitivity (Fonseca, 2009).  
 One of the mains questions that remains it is the physiological process that leads 
to decrease of β-cell function in T2D, being at this point the glucotoxicity, whereby β-
cells become sensitized to the presence of glucose, and lipotoxicity, whereby 
accumulated fatty acids and their metabolic products deleteriously affect β-cells, the 
mains hypothesis. In glucotoxicity, chronic hyperglycemia depletes insulin secretory 
granules from β-cells, lessening the amount of insulin available to be released in 
response to new glucose stimuli. Lowering glucose levels permits regranulation of β-
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cells and a better acute insulin response follows. In lipotoxicity, prolonged increases in 
free fatty acid levels adversely affect the conversion of pro-insulin to insulin and 
eventually affect insulin secretion. Fatty infiltration of pancreatic islets may also 
contribute to β-cell dysfunction, and pancreatic fat correlates negatively with β-cell 
function. The concepts of gluco- and lipotoxicity remain hypotheses; the exact 
mechanisms responsible for impaired β-cell function have yet to be conclusively 
proved. In addition to glucose and lipid deposition in the pancreas, pancreatic islets 
from type 2 diabetic patients are known to have amyloid deposits, fibrosis, and 
increased cell death, associated with an inflammatory response (exacerbates insulin 
resistance), which has long been associated with the development and progression of 
type 2 diabetes   (Fonseca, 2009; Ozougwu, 2013).  
 Thus, in type 2 diabetes, excessive carbohydrate and fat intake causes 
hyperinsulinemia in association with increased hepatic lipoprotein secretion, adipose 
tissue growth, and increased free fatty acid levels in genetically susceptible individuals. 
Together with postprandial hyperglycemia, elevated free fatty acid levels cause muscle 
and liver insulin resistance and increase hepatic glucose production. The same stimuli 
also facilitate β-cell compensation by promoting insulin secretion and biosynthesis as 
well as β-cell growth. In late stages, however, the progressive rise in insulin resistance, 
combined with alterations in β-cell gene expression and signaling induced by rising 
levels of free fatty acids, cause β-cell failure. Overt diabetes occurs as a result of this β-
cell decompensation, with altered insulin secretion and apoptosis as possible 
contributing factors (Shan et al., 2014).  
1.2.3.5 Main features of Type 2 diabetes 
 
 The role of impaired insulin secretion and insulin resistance has been discussed 
all over the years, being pointed as the main causes of T2D. However in the last years 
has emerged the contribution of impaired insulin clearance to development of T2D. 
 Insulin resistance (IR) is defined clinically as the inability of exogenous or 
endogenous insulin to increase glucose uptake and utilization in an individual as much 
as it does in a normal population. IR is linked to several diseases that represent 
tremendous burdens to health system resources, like obesity, metabolic syndrome, 
nonalcoholic fatty liver disease (NAFLD), T2D, and atherosclerotic heart disease. 
Insulin resistance may be either peripheral (which refers to diminished insulin-mediated 
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uptake of glucose by skeletal muscle and depends primarily on the failure of glucose 
transporter type 4 (GLUT4) expression and translocation to the plasma membrane) or 
hepatic insulin resistance (which describes impaired suppression of hepatic glucose 
production, and largely accounts for hyperglycemia and glucose intolerance) (El-
Zayadi, 2010; Sansbury & Hill, 2014). Insulin action is the consequence of insulin 
binding to its plasma membrane receptor and is transmitted through the cell by a series 
of protein-protein interactions. Two major cascades of protein-protein interactions 
mediate intracellular insulin action: one pathway is involved in regulating intermediary 
metabolism and the other plays a role in controlling growth processes and mitoses. The 
regulation of these two distinct pathways can be dissociated. Indeed, some data suggest 
that the pathway regulating intermediary metabolism is diminished in type 2 diabetes 
while that regulating growth processes and mitoses is normal. Several mechanisms have 
been proposed as possible causes underlying the development of insulin resistance and 
the insulin resistance syndrome. These include: (1) genetic abnormalities of one or more 
proteins of the insulin action cascade (2) fetal malnutrition (3) increases in visceral 
adiposity (Samuel & Shulman, 2012).  
 The earliest detectable defect in β-cell function is frequently a reduction in first-
phase of insulin secretion. First-phase insulin release is normally reduced in individuals 
with plasma glucose in upper ranges of normal and is essentially absent in people with 
fasting hyperglycemia (Gerich, 2002). The concept received further support from 
studies of subjects with impaired glucose tolerance (IGT), showing that these generally 
had reduced plasma insulin levels at 30 min after glucose ingestion and “normal or 
increased” plasma insulin levels at 120 min (Gerich, 1997). The assumption has been 
made assuming that the 30-min response reflected first phase insulin release, whereas 
the 120-min response reflected second-phase insulin release. Thus, it is accepted that 
reduced first-phase insulin release is responsible for the development of IGT (Natham et 
al., 2007). 
 A problematic that have receive further discussion during the years related to the 
pathogenesis of type 2 diabetes is the debate whether is insulin resistance or impaired β-
cell function the primary defect in this pathology. By primary defect, the underlying 
genetic defect is meant. It seems well established that T2D is a polygenic disorder in 
which both hereditary and environmental or acquired factors are involved, and both of 
these factors can affect β-cell function and insulin sensitivity (Shah & Vella, 2014). It is 
know that the normal islet adjusts its function in order to compensate for insulin 
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resistance. However in interpreting the appropriateness of insulin secretion, it should 
take into consideration not only the stimulus (i.e., plasma glucose level), but also the 
prevailing insulin sensitivity. For instance, during a hyperglycemic clamp experiment in 
which plasma glucose was increased to comparable levels in a lean and obese subjects, 
plasma insulin responses in the lean individual compared with those of the obese 
individual would be considered inappropriate and would suggest an impaired β-cell 
function. In the past, these variables were generally not taken into consideration and 
because of this, the concept that insulin resistance precedes β-cell failure in the 
progression to type 2 diabetes became widely accepted and consequently so did the 
concept that insulin resistance was the primary genetic component of type 2 diabetes 
(Gerich, 2002). This concept does not explain why the majority of obese individuals, 
who obviously are insulin resistant, do not develop diabetes. If one accepts that the 
normal β-cell adjusts its function to compensate for insulin resistance, then one could 
explain the development of IGT and type 2 diabetes as a failure of β-cell compensation 
and that this may be the genetic basis for type 2 diabetes. Acceptance of this proposition 
does not exclude the effect of environmental/acquired factors (e.g., glucose toxicity, 
lipotoxicity, and amyloid accumulation in islets) might also be involved. 
 
1.3.2.5.1 Insulin clearance 
  Insulin clearance is a feature of all insulin sensitive tissues and an integral 
component of insulin metabolism. This process regulates the cellular response to the 
hormone by decreasing insulin availability and mediating certain aspects of insulin 
action. At physiological concentrations, uptake is mediated primarily by the insulin 
receptor with a smaller contribution from nonspecific processes. At higher 
concentrations, nonreceptor processes start to assume greater importance. Insulin has a 
short plasma half-life (4–6 min), as would be expected from the necessity to respond 
rapidly to changes in blood glucose. The modeling of insulin kinetics is a technically 
difficult process, and the mathematical ramifications of whole-body systems are 
extremely complex and are been development. The liver is the primary site of insulin 
clearance. Although C-peptide passes through the liver without significant extraction, ~ 
70% of the secreted insulin is cleared by the hepatocytes before entering the systemic 
circulation being the remainder cleared by the kidneys and muscles. Therefore, the rate 
of hepatic insulin clearance is an important regulator of peripheral glucose metabolism 
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(Bojsen-Møller et al., 2013). A reduction in hepatic insulin clearance is typically found 
after oral glucose or meal ingestion, thereby increasing the systemic availability of 
insulin to respond an increase in of glucose levels. The mechanisms underlying this 
phenomenon are largely unknown (Meier et al., 2007). Changes in insulin clearance can 
occur under different physiological conditions and can be related with pathological 
states. Clearance rates for insulin decrease in glucose intolerance, obesity, in particular 
abdominal obesity, hypertension, hepatic cirrhosis, and nonalcoholic fatty liver disease. 
Although the plasma concentration of insulin is largely determined by its rate of 
secretion and clearance, some evidences suggest that increased insulin resistance is 
associated with reduced insulin clearance (Lee et al., 2013). Reduced insulin clearance 
has important physiological functions; for example, animal models have shown that 
decreased insulin clearance serves as a compensatory mechanism to preserve b-cell 
function and to maintain peripheral insulin levels in the states of insulin resistance (Kim 
et al., 2007). In addition, insulin clearance has been found to be a highly heritable trait 
in Mexican Americans, and specific haplotypes in the AMPD1 gene were associated 
with variation in insulin clearance (Goodarzi et al., 2005).  
 Despite the potential role of insulin clearance in the etiology of diabetes, little is 
known about the factors that are independently associated with decreased insulin 
clearance and need to be further investigated. As mentioned above the liver is the 
primary site of insulin clearance, when this is release in the portal vein. A higher 
percentage of portal insulin is removed during first pass transit, but this percentage 
varies widely under different conditions. Hepatic uptake is not a static process, but 
rather is influenced by both physiological and pathophysiological factors. Prolonged 
increases in portal insulin levels also result in reduced clearance due to receptor down-
regulation. Removal of insulin from the circulation does not imply immediate 
destruction of the hormone. A significant amount of receptor-bound insulin is released 
from the cell and reenters the circulation with possible biological functions. Nutrient 
intake alters insulin clearance. The glucose-induced increase in insulin secretion may 
decrease hepatic fractional extraction (Duckworth, 1998). Given the importance of the 
liver in insulin clearance, it is expected that liver disease may result in a decrease or at 
least an impairment in insulin clearance process, although not all studies agree 
(Antoniello et al., 1989). The decreased clearance is probably due to reduced hepatic 
function. The reduced hepatic clearance is also associated with reduced insulin 
sensitivity, again supporting the relationship between insulin degradation and insulin 
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resistance. The primary cellular mechanism for hepatic uptake and degradation of 
insulin is a receptor-mediated process. Most hepatic uptake is due to hepatocytes, with 
Kupfer cells contributing about 15% to the total (Duckworth, 1998). 
 The kidney is the major site of insulin clearance from the systemic circulation, 
removing around 50% of peripheral insulin. In addition, the kidney removes 50% of 
circulating proinsulin and 70% of c-peptide by glomerular filtration. Insulin analogs are 
also cleared by kidney. Insulin not cleared by liver and kidney is ultimately removed by 
other tissues. All insulin-sensitive cells remove and degrade the hormone. After liver 
and kidney, muscle plays the major role in insulin removal (Duckworth, 1998). The 
main enzymes involve in this process are the insulin-degrading enzyme (IDE), an 
insulinase, which degrades insulin with a high degree of specificity and protein disulfide 
isomerase (PDI) whose the main role is to catalyze protein folding in the endoplasmic 
reticulum (Hwang et al., 2007; Xu et al., 2014; Duckworth, 1998). It is believed that the 
participation of these two enzymes occur in a in a sequential manner with disulfide 
cleavage and subsequent proteolysis. The mechanism proposed is that the initial 
degradative step occurs in endosomes with two or more cleavages in the B chain of 
insulin by IDE. This is followed by reduction of the disulfide bonds by PDI, or a related 
enzyme, yielding an intact A chain and several B chain fragments. The insulin 
fragments are then further cleaved, probably by multiple proteolytic systems, including 
lysosomes and produce intracellular fragments of insulin with potential biological 
activity (Duckworth, 1998).  
 
1.3.2.5.2 Nonalcoholic Fatty Liver Disease and Type 2 Diabetes 
 
 Nonalcoholic fatty liver disease (NAFLD) involves a spectrum of pathological 
conditions, ranging from simple steatosis to nonalcoholic steatohepatitis (NASH) and 
cirrhosis, in the absence of excessive alcohol consumption (typically a threshold of<20 
g/d for women and < 30 g/d for men is adopted). NAFLD has been becoming a growing 
public health problem worldwide reaching epidemic proportions, and is the most 
common cause of chronic liver disease in many developed countries. NAFLD increases 
the risk of end-stage liver disease, and NAFLD-induced liver failure is one of the most 
important reasons for liver transplantation (Targher& Byrne, 2013). Because NAFLD 
and T2D share pathogenic abnormalities of excess adipose tissue and insulin resistance, 
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both frequently co-occur, and the several outcomes of each disease can overlap in 
affected individuals. T2D is a risk factor for progressive liver disease and liver-related 
death in patients with NAFLD, and NAFLD may be a marker of increased 
cardiovascular risk and mortality in subjects with T2D, whereas patients with both 
NAFLD and T2D have poorer prognoses in terms of increased cardiovascular and liver-
related mortality. Insulin-resistant patients with liver steatosis, compared with insulin-
sensitive individuals, have higher insulin responses and lower hepatic insulin clearance, 
leading to hyperinsulinemia (Chai et al., 2014). 
 NAFLD is a manifestation of pathological ectopic fat accumulation coupled with 
a low-grade chronic inflammatory state in liver, which is an organ not able to 
accumulate fat. This condition is still poorly recognized by endocrinologists and general 
physicians, and recent work is now suggesting putative mechanisms by which NAFLD 
increases risk of developing T2D and worsens glycemic control, contributing to the 
pathogenesis of major chronic complications of T2D, such as cardiovascular disease and 
chronic kidney disease (CKD) (Targher & Byrne, 2013). The amount of intrahepatic fat 
closely correlates with serum liver enzyme activity and the number of metabolic 
syndrome features (Kotronen et al., 2007). Patients with T2D have approximately 80% 
more intrahepatic fat content than age-, sex-, and body weight-matched nondiabetic 
controls, and their serum liver enzymes are less representative of the severity of 
intrahepatic fat accumulation. The prevalence of NAFLD in people with T2D ranges 
from approximately 50 to 75%. A recent study with ultrasound of near of 3000 
unselected patients with T2D reported a prevalence of NAFLD of 69.5% (Targher et al., 
2007). Notably, patients with NAFLD and T2D are also more likely to develop the 
more advanced forms of NAFLD, such as NASH, advanced fibrosis, cirrhosis, and in 
some cases hepatocellular carcinoma. It is known that T2D along with obesity and older 
age are among the strongest risk factors for advanced fibrosis and cirrhosis. The 
presence of NAFLD among patients with T2D appears to be an important risk factor for 
all-cause mortality. In a study with T2D patients was reported that those with NAFLD 
had a 2.2-fold increased risk of all-cause mortality compared with those without 
NAFLD (Adams et al., 2010); the most common causes of death were malignancy, 
CVD, and liver-related complications. However the possible underlying mechanisms 
leading to CVD and CKD in patients with T2D and NAFLD are complex and not yet 
fully understood (Obika & Noguchi, 2012).  
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 However, the most accepted underlying mechanisms linking NAFLD with T2D 
and poor glycemic control may originate from the development of an expanded and 
inflamed visceral adipose tissue mass. In this situation, the liver may function as both 
the target organ and the source of the resulting systemic abnormalities that promote not 
only increased risk of T2D but also increased risk of chronic vascular complications. 
Fat accumulation in the liver is influenced (in order of importance) by the delivery of 
extrahepatic free fatty acids (FFA) (principally from adipose tissue), hepatic de novo 
lipogenesis, and the supply of dietary fat to the liver. Importantly, the main processes 
regulating hepatic fat metabolism also have the potential to affect hepatic glucose 
production. For example, with respect to the link between hepatic steatosis, IR, and 
dysglycemia, dietary carbohydrate intake increases glucose and insulin levels, which in 
turn activates 2 key hepatic transcription factors that promote hepatic de novo 
lipogenesis and hepatic glucose production (carbohydrate response element binding 
protein and sterol response element binding protein-1c). Whether IR causes intrahepatic 
triglyceride accumulation or vice versa is the subject of much research in nowadays 
(Obika & Noguchi, 2012; Targher & Byrne, 2013). 
 Liver biopsy is considered the gold standard for the diagnosis and assessment of 
both NAFLD and NASH but has several limitations, such as sampling variability, 
invasiveness and expense. Thus the diagnosis is mainly realized based on equation that 
has in count several parameters that can indicate liver disease.  
 
1.3 Family History of Diabetes 
 Family history of diabetes has been recognized over the years as an important 
risk factor of the disease. Family medical history represents valuable genomic 
information because it characterizes the combined interactions between environmental, 
behavioral, and genetic factors. However the results regarding to this risk factor have 
presented highly heterogeneity, being inconsistent among the different population 
analyzed. Thus it is fundamental keep studying the importance of FHD in the 
development of the three more prevalent types of diabetes, namely T1D, LADA and 
T2D. 
 Although more than 85% of patients with T1D do not present a positive family 
history for the disease, one of the major risk factor is a presence of first-degree relative 
type 1 diabetic in the family. Familial aggregation of type 1 diabetes has been 
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recognized for many years, and ~ 10–15 % of newly diagnosed children have a first-
degree relative affected with type 1 diabetes. The risk of developing islet autoimmunity 
varies depending on which relative(s) have type 1 diabetes. The risk also depends on the 
number of relatives with type 1 diabetes (Redondo & Eisenbarth, 2002). Analysis of the 
BABYDIAB cohort found that children’s risk for islet autoantibodies was markedly 
increased if both parents or a parent and a sibling had type 1 diabetes compared with a 
single affected family member. Among first-degree relatives, siblings are at a higher 
risk (5%–10% risk by age 20) than offspring (the risk for T1D in siblings of patients is 
15-fold higher than the risk for T1D in the general population); offspring of diabetic 
fathers are at a higher risk (approximately 12%) than offspring of diabetic mothers 
(approximately 6%) (Ziegler et al.,1999). 
 Regarding to importance of family history of diabetes to development of LADA, 
this has been a subject understudied. The majority of the studies have been focus on 
type 1 and type 2. Interesting recent reports have shown familial clustering of type 1 
and type 2 diabetes genes and have suggested that selected susceptibility gene variants 
may be involved in the pathogenesis of type 1 and type 2 diabetes. The results of the 
Nord-Trøndelag Health Study showed that family history of diabetes, although the type 
of diabetes in the relatives was unknown, was also a strong risk factor for the 
development of LADA, highlighting the importance of use FHD as a tool to screen the 
presence of diabetes (Carlsson et al., 2007)  
 With respect to importance of family history of diabetes for development of 
T2D, evidence for a strong genetic element of type 2 diabetes susceptibility is suggested 
by the high incidence in certain racial/ethnic populations, high concordance in 
monozygotic twins compared with dizygotic twins, and high incidence among first-
degree relatives of persons with type 2 diabetes. The complex pathophysiologic nature 
of diabetes supports the idea that multiple biologic and/or chemical pathways are 
implicated in the development and progression of the disease, and numerous genetic 
loci have been investigated in the search for genetic determinants of the disease 
(Olokoba et al., 2012). Identifying susceptibility loci for diabetes, however, has been 
difficult because of the multiple genes involved and strong environmental contributing 
factors. Individuals who have a family history of diabetes presents a risk two to six 
times higher of develop type 2 diabetes compared with individuals with no family 
history of the disease. In this field is detected too, not in all, but in some studies an 
excess of maternal transmission of type 2 diabetes (i.e., greater likelihood of diabetes in 
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offspring of affected mothers than affected fathers, unlike what occurred in type 1 
diabetes (Valdez et al., 2007; Kaeter et al.,1999) . 
 Therefore, the use of family history as part of a comprehensive risk assessment 
for an individual can be crucial in the prevention, early detection, and treatment of 
diabetes. On a population level, family history may help tailor health promotion 
messages for specific population groups who are included in this high risk group. 
Beside many studies have been made analyzing the influence of FHD to risk of 
diabetes, according to our knowledge no one have been focus in analyzing the type of 
diabetes that people are in risk to develop according to type of diabetes presented in first 
relatives. Thus, this work elaborated with a large population, is expected to bring 
important new evidences especially for clinics, in order to become FHD a higher robust 
tool to analyze the risk of develop diabetes mellitus. 
 
2. Objectives  
 
 This study will be focused on the risk of developing diabetes in the presence of 
first-degree relatives with diabetes.  
Objective 1 – characterize the Family History of people with Diabetes according to the 
type of diabetes 
Objective 2 – Assess the risk of developing diabetes in different first degree relatives of 
people with diabetes 
Objective 3 – Differentiate dysglycemic states in the high risk population of relatives of 
people with diabetes. 
 
Our hypotheses are:  
Hypothesis 1 - First-degree relatives of people with diabetes represent a high risk factor 
group to develop diabetes.  
Hypothesis 2 – First degree relatives of people with diabetes are a heterogeneous group 
for the risk of developing diabetes 
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Hypothesis 3 – Insulin clearance during an OGTT differentiates metabolic states 
between dysglycemic categories 
3. Subjects and Methods 
 The present work was performed in Portuguese Diabetes Association (APDP - 
Associação Protectora dos Diabéticos de Portugal), Lisbon. APDP is the largest 
clinical of diabetes in Portugal, with over 125,000 registered patients, thus it is a 
privileged institution to realize investigations studies having access to a higher number 
of population. The study realized in this master thesis can be divided into two different 
parts: the first one, a clinico-epidemiological study, that aimed to analyze the 
relationship between the family history of diabetes and the prevalence of diabetes 
among the patients of APDP in the last five years (2009-2013); the second one, a clinic 
study that aimed to analyze the possible metabolic alterations in a high risk group 
among first degree relatives of type 2 diabetic patients. Both parts of this project were 
realized based on evidences that a family history of diabetes is indeed a major risk 
factor to develop the disease. Thus, this work pretends to highlight the importance of 
FHD as a preventive tool for diabetes, expecting to provide new important evidences 
that allow an earlier intervention in this risk group in order to decrease the epidemic 
numbers of diabetes observed all over the word. All the procedures here realized were 
previously reported and approved by the ethics committee of APDP. 
3.1 Study Group 
3.1.1 Study 1 
 The group study chosen was comprised by the patients of APDP with T1D, 
LADA and T2D within a period of five years (2007-2013).These three types of diabetes 
are the most prevalent among the patients of APDP. The patients of APDP are citizens 
from Portugal, natives and/or immigrants, thus it is possible that the present group has 
some heterogeneity. We make an analysis of the FHD available in the clinic file of 
diabetics, which was elaborated by the doctor in the first appointment in APDP based 
on information provided by the patients. In an initial phase 24.788 clinic files were 
analyzed, however 7.914 were incomplete, thus these were removed, being the viable 
population for analyzes comprised by 16.874 clinic files of people with diabetes. The 
main reason that explains the incomplete files is the fact that some patients 
demonstrated lack of knowledge about their family history of diabetes. The analyzed 
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population for the present study included 3013 patients (17.86%) with T1D, 373 with 
LADA (2.21%) , and 13488 (79.93%) with T2D.  
3.1.2 Study 2  
 The chosen study group to this work was the non-diabetic siblings of T2D 
subjects, because they are a low hanging fruit since they are at an inherently higher risk 
of progressing to T2D and they are also likely more motivated to undergo testing and 
lifestyle changes to prevent T2D. The recruitment of T2D-siblings was made in two 
different parts: 1) in waiting rooms we inquired the T2D patients about the existence of 
non-diabetic siblings and if they would be available to come to APDP in order to realize 
the present study. In case of positive answer, we asked the name and the telephone 
number of T2D-sibling; 2) then, we contacted the T2D-siblings by telephone, 
explaining all the details involved in the study, and in the case of those who matched all 
the conditions, we scheduled the analysis. The analyzed population in the present study 
was composed by 23 siblings of type 2 diabetics, 8 were males and 15 were females.  
 
3.2 Study design 
  
3.2.1 Study 1 
 It was selected the data from 2009 to 2013, mainly because within this range of 
time it was possible to achieve a significant amount of clinic files in order to aim our 
goal. The first step in data proceeding (after exclude all the incomplete files) was to 
evaluate the prevalence of each type of diabetes, calculating the number of men and 
women with T1D, LADA and T2D, as well as the average age observed in each group. 
After this, the patients’ files among each group of diabetic were separated in individuals 
with FHD and those without FHD. The people with FHD were categorized in two 
different groups according to the type of relatives that had diabetes: 1) at least first 
degree relatives 2) only second degree relatives. It is important to bear in mind that the 
same process of all analysis realized in each type of diabetic group without 
distinguishing between gender and age was applied.    
 Next, we analyzed the prevalence of diabetes in first-degree relatives, therefore 
parents, siblings and offspring. We started to analyze the presence of diabetes in 
parents, separating the patients in three groups: 1) only mothers with diabetes, 2) only 
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fathers with diabetes 3) both parents with diabetes. Within each group, it was 
distinguished the type of diabetes presented by parents. After, we analyzed the presence 
and the type of diabetes present in offspring and siblings, completing the process of 
analysis of first degree relatives. We just had access to complete information about 
FHD of patients with first degree relatives with diabetes, therefore it was only possible 
for us to realize a further exploration in this group. We categorized the clinic process of 
these subjects according to different combinations of FHD, achieving the following 
categories: 1) only parents; 2) only siblings; 3) only siblings with T1D; 4) only siblings 
with T2D; 5) only siblings with T1D and T2D; 6) parents and siblings. 
 In these entire categories that were here described, it was calculated the 
prevalence. The odds ratio was calculated too, enabling to realize directly comparisons 
among the different types of diabetes analyzed in this research project. 
 3.2.2 Study 2 
 The analyses were carried out in the fasting state. Thus, it was asked to siblings-
T2D not to eat or drink anything except water for 8 to 10 hours before the OGTT 
modified. In the day of analysis, after the subjects had been conducted to the blood 
collecting room, the procedures were explained and the informed consent was signed. 
Then, the clinic information (e.g. previous diseases, medication), weight, height were 
obtained and the waist circumference fasting state was measured before the beginning 
of OGTT modified. The first blood sample was collected in the fasting state, and then 
the subject ingested the glucose solution (75g of glucose /200mL of H2O). In this first 
collection 1 serum tube (9ml) and two tubes (3mL per tube) of whole blood (1 for 
plasma, and 1 for whole blood) were obtained. The next blood collections were realized 
at 30, 90 and 120 minutes after the ingestion of glucose solution. At this three last 
points, only was necessary collected 2 different tubes, 1 tube for serum (9ml) and 1 tube 
for plasma (3 ml). After all the process conclude, the serum samples were analyzed by 
Olympus AU640 and Liaison auto-analyzers and the whole blood samples were 
assessed in Automated Hematology Analyzer Sysmex XT-1800i and Variant II Turbo. 
This process was conduct by the specialized laboratory technicians of APDP. After all 
the parameters analyzed, the blood samples were stored in a biobank at – 80ºc, in order 
to be used in further investigations that are not determined yet. 
 This work was an observational study involved in a large project already 
approved by FCT, namely “Anticipating diabetes and diabetic wounding for siblings of 
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Type 2 diabetics”. However it allows us an effective detection of people with unknown 
type 2 diabetes and people in a state of prediabetes. Thus, to these people with 
deregulation at glycaemia metabolisms we applied some interventional measures: for 
prediabetic and unknown type 2 diabetic subjects, we scheduled an appointment with 
the project coordinator, Prof.  Doctor João Filipe Raposo; for subjects with normal 
glucose tolerance we sent the results to their homes giving information that all the 
parameters were within a normal range. 
3.3 Analysed parameters  
3.3.1 Study 1 
 In order to analyze the relationship between FHD and the prevalence of diabetes, 
was solicited to informatics of APDP a file with appropriate information. The file 
contained the gender, age, number of process, and information about FHD. The 
information about FHD was obtained in the first appointment at APDP, in which each 
patient was inquired about the presence of diabetes in first degree relatives. Thus, it was 
possible to analyze all the information about the presence of diabetes in parents, siblings 
and offspring, including the type of diabetes present on them. Regarding to the presence 
of diabetes in second degree relatives, the computer system that will allow the security 
of these data is in development, thus we only had access if the patients had or not 
knowledge about the presence of second degree relatives with diabetes (indiscriminate).   
3.3.2 Study 2 
The parameters that were analyzed in blood serum and in whole blood are described in 
table 4: 
Table 4 - Parameters analyzed and methods used on serum and whole blood samples at different times. 
Serum 0’ 
Insulin 
(Chemiluminescence, according to Liaison Insulin Kit, DiaSorin) 
C-Peptide 
(Chemiluminescence, according to Liaison C-peptide Kit, DiaSorin) 
Glycose 
(Hexokinase method UV, according to Olympus AU640 Glucose Kit, Beckman Coulter) 
Free Fatty Acids 
(Enzymatic endpoint method, according to NEFA FS Kit, DiaSys) 
Triglycerides 
(Colorimetric enzymatic method, according to Olympus AU640 triglyceride kit, Beckman Coulter) 
Alanine transaminase (ALT)   
(UV cinetic assay, according to Olympus AU640 ALT Kit, Beckman Coulter) 
Aspartate aminotransferase (AST)  
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In the 30, 90 and 120 minutes the following parameters were analyzed in serum: 
Serum (30’,90’,120’) 
Glycose 
Free Fatty Acids 
Insulin 
C-Peptide 
 
  Based on the OGTT the T2D-siblings were categorized according to glucose 
tolerance status in impaired glucose tolerance (IGT), impaired fasting glucose (IFG), 
impaired fasting glucose plus impaired glucose tolerance (IFG+IGT), normal glucose 
tolerance (NGT), and T2D. After this, the three main physiological processes involved 
in the regulation of insulin levels were evaluated: insulin secretion, insulin action and 
insulin clearance. The measure of insulin and the c-peptide levels allow us the 
evaluation of insulin secretion. The action of insulin was assessed by the application of 
HOMA-IR and OGIS, whereas insulin clearance was estimated from the molar C-
peptide-to-insulin ratio and from the respective areas under the curve. Hepatic steatosis 
and development of fibrosis are  features that are often found in patients with type 2 
diabetes, thus we decided to evaluate the fatty liver index (FLI) and the NAFLD fibrosis 
score (NFS). 
(UV cinetic assay, according to Olympus AU640 AST Kit, Beckman Coulter) 
Gamma-glutamyl transpeptidase (γ-GT)  
(colorimetric cinetic assay, according to Olympus AU640 γ-GT Kit, Beckman Coulter) 
Albumin  
(colorimetric method, according to Olympus AU640 Albumin Kit, Beckman Coulter) 
HDL  cholesterol 
colorimetric method, according to Olympus AU640 HDL-Cholesterol Kit, Beckman Coulter 
LDL  cholesterol 
 colorimetric method, according to Olympus AU640 HDL-Cholesterol Kit, Beckman Coulter 
Total cholesterol  
colorimetric method, according to Olympus AU640 total cholesterol  Kit, Beckman Coulter 
 
Whole blood 0’ 
Platelets 
(Hydrodynamic Focusing Direct Corrent Detection Method, in Automated Hematology Analyzer 
Sysmex XT-1800i )  
Glycated hemoglobin (HbA1c) 
(HPLC, according to Variant II Turbo Hba1c Kit – 2.0, Bio-Rad Laboratories) 
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3.4 Techniques and methods  
3.4.1 Study 1 
3.4.1.1 Classification of the types of diabetes in APDP patients  
This process was exclusively realized by clinics of APDP. The first step was evaluated 
if the disease was present in the subject. The criteria used in this process are presented 
in the table 5: 
 
Table 5- Criteria for the diagnosis of diabetes (From American Diabetes Association, 2010). 
 
 
After confirmation of diabetes diagnosis, the individuals were categorized according to 
the type of diabetes. The main criteria for classification of T1D, LADA and T2D are the 
following (table 6): 
 
Table 6 - Criteria followed to distinguish among the different types of diabetes. 
 
Type of Diabetes Some criteria 
Type 1 Diabetes Decreased C peptide levels and/or 
presence of GADA and ICA and/or 
treatment with insulin required at 
diagnosis and/or loss of weight and/or 
polyuria, polyphagia    
A1C≥ 6.5%. The test should be performed in a laboratory using a method that is NGSP 
certified and standardized to the DCCT assay
* 
Or 
FPG ≥ 126 mg/dl (7.0mmol/l). Fasting is defined as no caloric intake for at least 8h.
* 
Or 
2-h plasma glucose ≥ 200mg/dl (11.1mmol/l) during an OGTT. The test should be performed 
as described by the world Health Organization, using a glucose load containing the equivalent 
of 75g anhydrous glucose dissolved in water
* 
Or 
In a patient with classic symptoms of hyperglycemia or hyperglycemia crisis, a random plasma 
glucose ≥ 200 mg/dl (11.1 mmol/l) 
In the absence of equivocal hyperglycemia, criteria 1 – 3 should be confirmed by repeat 
testing 
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LADA Adult age of onset (> 30 years of age) 
and/or  presence of at least one 
circulating autoantibodies 
(GADA/ICA/ IAA/IA-2) and/or initial 
insulin independence (for the first six 
months) 
Type 2 Diabetes Insulin resistance and/or no islet cell 
autoantibodies and/or obesity and/or  
sedentary lifestyle 
 
Note: The majority of the cases were diagnosed only according to the characteristic 
clinic symptoms of each type of diabetes. In the cases that presented some uncertainty 
laboratorial exams were realized to confirm the diagnosis.  
3.4.1.2 Prevalence calculation 
 In order to calculate the prevalence in each category, the number of individuals 
was divided by the total number of the individuals with that type of diabetes. For 
instance, all the categories created in analysis of type 1 diabetic were divided by 3006 
and obviously multiplied by 100% to obtain a percentage.  
3.4.1.3 Calculation of the Odds Ratio 
 The odds ratio (OR) is a measure of association between an exposure and an 
outcome. The OR represents the odds that an outcome will occur given a particular 
exposure, compared to the odds of the outcome occurring in the absence of that 
exposure. Odds ratios are most commonly used in case-control studies, however they 
can also be used in cross-sectional and cohort study designs as well (with some 
modifications and/or assumptions). 
 Odds ratios are used to compare the relative probability of the occurrence of the 
outcome of interest (e.g. disease or disorder), giving exposure to the variable of interest 
(e.g. health characteristic, aspect of medical history). The odds ratio can also be used to 
determine whether a particular exposure is a risk factor for a particular outcome, and to 
compare the magnitude of various risk factors for that outcome. According to the results 
obtained when the OR is used, the following conclusions can be assumed:  
 OR=1 Exposure does not affect odds of outcome 
 OR>1 Exposure associated with higher odds of outcome 
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 OR<1 Exposure associated with lower odds of outcome 
 The 95% confidence interval (CI) is used to estimate the precision of the OR. A 
large CI indicates a low level of precision of the OR, whereas a small CI indicates a 
higher precision of the OR. It is important to note however, that unlike the p value, the 
95% CI does not report a measure’s statistical significance. In practice, the 95% CI is 
often used as a proxy for the presence of statistical significance if it does not overlap the 
null value (e.g. OR=1) - evidence for lack of association between the exposure and 
outcome (Szumilas, 2010). 
 The necessary formula to calculate OR is the following: 
 
 
 
  
 
 
Confidence intervals are calculated using the formula that is shown below: 
  
  
 
Normally, the OR is calculated with the resource of a control group, however in our 
case we just had access to diabetic individuals, thus we did a direct comparison among 
the different types of diabetes, something that as far as we know hadn’t been done 
before. This away, the estimation based on the concept of Odds Ratio that we obtained 
shows the risk of developing one type of diabetes instead the other analyzed types of 
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diabetes. The following example will explain the process that we use to calculate odds 
ratio in this work: 
1) What type of diabetes is more likely to develop, having a mother with 
Diabetes (not discriminate): 
 
 
 T1D LADA T2D 
Only mother with 
diabetes 
N = 264/3013 
8.76% 
N = 61/373 
16.35% 
N = 2765/13488 
20.50% 
 
 
Let´s begin to calculate the risk of develop T2D instead T1D or LADA, having a 
mother with Diabetes: 
 
a = the exposed cases are the type 2 diabetic with mother with diabetes 
(a=2765) 
b = the exposed non-cases are the 2 diabetic that do not have a diabetic 
mother (b= 13488 – 2765  b = 10723) 
c = exposed non-cases are the people with a diabetic mother that do not have 
type 2 diabetes (c = 264 + 61  c = 325) 
d = unexposed non-cases are the people that do not have a diabetic mother 
among type 1 and LADA and do not have type 2 diabetes. 
 (d = (3013+373) – (264+61)  d = 3061 
OR(T2D) = 
2765 𝑥 3061
10723 𝑥 325
OR= 2.43 ( 95% C.I = 2.15 - 2.74) 
  
We can repeat the same process for T1D and LADA, in order to compare the OR and in 
this away achieve which type is more probably to develop, having a mother with 
diabetes: 
      OR (LADA) =
61 𝑥 13472
3029 𝑥 312
 OR (LADA) = 0.87 (95% C.I=0.66-1.15)  
 
Note: Non significant because it spans the null value. 
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     OR (T1D) =
264 𝑋 11035
2826 𝑋 2749
 OR (T1D) = 0.375 (95% C.I  = 0.33 - 0.43) 
Comparing the three OR obtained we can thus conclude that the risk of developing T2D 
instead T1D or LADA is higher, having a mother with diabetes mellitus.  
3.4.2 Study 2 
3.4.2.1 Oral Glucose Tolerance Test (OGTT) 
 The glucose tolerance test was first described in 1923 by Jerome W. Conn. This 
test was based on the fact that after carbohydrate ingestion, normal patient will rapidly 
return to normal levels of blood glucose after an initial spike. Thus, OGTT has the 
capacity to identify defects in the regulation of glucose metabolism after a meal, in this 
case after the ingestion of a higher concentrate glucose solution, allowing the 
identification of IGT subjects. The OGTT is currently the gold standard for the 
diagnosis of diabetes. The interpretation is based on venous plasma glucose results 
before and 2 hours after a 75 g oral glucose load (Harris et al., 2013). However the 
number of blood collections during the test is variable, depending on the purpose of the 
study. In our case, we decided four times because previous studies show us that the 30 
and 90 minutes are essential points to evaluate the three processes in regulation of 
insulin levels, something that is essential in order to maintain glucose homeostasis. The 
Royal Australian College of General Practitioners (RACGP) recommends an OGTT 
when the results of fasting or random blood glucose are equivocal (Figure 2.1): fasting 
100 mg/dL–125 mg/dL; random 100 mg/dL–199 mg /dL. An OGTT is unnecessary if 
fasting or random blood glucose values are clearly in the nondiabetic or diabetic range: 
fasting or random <100 mg/dL; fasting ≥ 125 or random ≥ 200mg/dL respectively. 
However, diagnosis should only be based on laboratory results, not results from a 
glucose meter. The test is also recommended to pregnant woman in order to detect 
gestational diabetes (Phillips, 2012).  
 
 
 
 
 
Fasting or Random:  
≤ 100mg/dL 
Fasting:  
100-124 mg /dl 
Random: 
100-199 mg/dL 
Fasting ≥ 125 mg/dL 
Random ≥200 mg/dL 
Diabetes Unlikely  Diabetes Uncertain Diabetes Likely 
OGTT 
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Figure 6 - The RACGP recommendations for when to perform an OGTT (from Harris et al., 2013) 
 
3.4.2.2 Serum preparation 
 The whole blood was collected to a vaccuette tube (9 ml) containing no 
anticoagulant and then centrifuged at 3500 rpm during 10 minutes at room temperature. 
The resulting supernatant is designated serum and it was used in automatic auto 
analyzers to assess several parameters.   
3.4.2.3 Whole blood preparation 
 The whole blood was collected to a vaccuette tube (3 ml) containing 
anticoagulant (EDTA) and it was used to assess platelets and HbA1c. 
3.4.2.4 Categorizing glucose tolerance in T2D siblings 
 The criteria adopted to categorize T2D siblings were based on American 
Diabetes Association (American Diabetes association, 2010). Regarding to fasting 
plasma glucose, the subject was categorized according to the following parameters in 
the table 7: 
Table 7- Parameters used to classify glucose tolerance according to fasting plasma glucose levels.  
Result Fasting Plasma Glucose (FPG) 
Normal Glucose Tolerance (NGT) less than 100 mg/dl 
Impaired Fasting Glucose (IFG) 100 mg/dl to 125 mg/dl 
Type 2 Diabetes (T2D) 126 mg/dl or higher 
 
After the OGTT, the subjects were categorized according to the following parameters 
(Table 8): 
Table 8 - Parameters used to classify glucose tolerance according to glucose levels after an OGTT (75g 
glycose). 
Result Oral Glucose Tolerance Test (OGTT) 
Normal Glucose Tolerance (NGT) less than 140 mg/dl 
Impaired glucose tolerance (IGT) 140 mg/dl to 199 mg/dl 
IFG + IGT 100 mg/dl to 125 mg/dl in fasting and 
140 mg/dl to 199 mg/dl after the OGTT 
Type 2 Diabetes (T2D) 200 mg/dl or higher 
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3.4.2.5 Homa-IR  
 Homeostasis model assessment as an index of insulin resistance (HOMA-IR), 
developed in 1985 by Matthews and coworkers, was used in this study as it is a simple 
and appropriate method in epidemiological studies where dynamic studies like the 
euglycaemic glucose clamp technique, though the gold standard, may not be feasible 
due to the degree of sophistication and cost of necessary apparatus. The HOMA-IR 
method requires measuring a single fasting plasma glucose and the corresponding 
fasting plasma insulin level and it is the most commonly used surrogate measure of 
insulin resistance in vivo, being the ability of identifying a proportion of subjects with 
insulin resistance without directly measuring insulin action. In terms of precision 
(reproducibility of measure), HOMA-IR is comparable to the glucose clamp technique.  
Although the HOMA-IR has been widely used, its cut-off for insulin resistance has not 
been conclusive. In addition, the HOMA-IR cut-off points to diagnose insulin resistance 
cannot be readily applied to all populations and may vary from race to race. In this work 
we used HOMA-IR to do a comparison among the different types groups of glucose 
tolerance. The formula was used to estimate the HOMA – IR is the following: 
𝑖𝑛𝑠𝑢𝑙𝑖𝑛 (
𝑚𝑈
𝐿
)𝑋 𝑔𝑙𝑢𝑐𝑜𝑠𝑒 (
𝑚𝑔
𝑑𝐿
)
405
(Esteghamati et al., 2012; Matthews et al.,1985).  
3.4.2.6 OGIS 
 OGIS (an acronym for Oral Glucose Insulin Sensitivity) is a method for the 
assessment of insulin sensitivity from the oral glucose tolerance test. OGIS provides an 
index which is analogous to the index of insulin sensitivity obtained from the glucose 
clamp. This complex mathematic model was developed in 2001 by Andrea Mari and 
has the advantage of considering the effect of insulin clearance on that. Unlike HOMA-
IR allows us to evaluate the insulin sensitivity during the OGTT, therefore during the 
fed state and not only in the fasting state. The necessary equations to determine OGIS 
Insulin sensitivity index are described in (Mari et al., 2001) or can be downloaded on 
http://webmet.pd.cnr.it/ogis/. This method calculates insulin sensitivity with a model-
derived equation of the form: OGIS = f (G0, G90, G120, I0, I90, I120, DO), where G and I 
are glucose and insulin concentrations (subscripts represent time instant) and DO is the 
oral glucose dose (g/m2 body surface area). The expression of f contains some 
parameters, chosen to maximize the agreement with the Hyperinsulinemic Euglycemic 
Clamp (HIEC). OGIS is a predictor of the HIEC insulin sensitivity, expressed as 
glucose clearance M/G, normalized to body surface area. The units of OGIS are thus 
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ml/min/m2 of body surface area. OGIS has been validated against a 120 mU/min/m2 
insulin infusion HIEC (by direct comparison of the glucose clearance values), instead of 
the most standard 40mU/min/m2 used in the previous methods. Formulas for a 3 h and 
2 h OGTT are also available (Patarrão et al., 2014). 
3.4.2.7 Fatty Liver Index (FLI) 
 Diagnosis of NAFLD is regarded as clinically problematic due to the invasive 
character of the gold-standard method of liver biopsy. Bedogni and co-workers 
introduced the FattyLiver Index (FLI), a multivariate model including biomarkers to 
accurately estimate presence of fatty liver. This estimation has already been applied by 
scientific investigations including large populations to determine the prevalence of fatty 
liver.  Presence of fatty liver was evaluated using the recently validated FLI. The index 
uses an algorithm based on body-mass-index (BMI), waist circumference (WCF), 
triglycerides (TG), gamma-glutamyl transferase (GGT), and natural logarithm (ln) as it 
follows: 
FLI = (e 
0.953*loge (triglycerides) + 0.139*BMI + 0.718*loge (ggt) + 0.053*waist circumference - 15.745
) / (1 + 
e0.953*loge (triglycerides) + 0.139*BMI + 0.718*loge (ggt) + 0.053*waist circumference - 15.745) * 100 
The subjects were classified into three groups: with FLI ≤ 20, who have a very low risk 
for fatty liver; with 20<FLI<60, an intermediate group; and the high risk group with FLI 
≥ 60(Bedogni et al., 2006). 
3.4.2.8 NAFLD  fibrosis score (NFS) 
 Patients with NASH can have a significant progression of fibrosis within a few 
years. Recently, a simple, noninvasive tool used for liver fibrosis assessment has been 
developed. This new scoring system, the NAFLD fibrosis score (NFS), is a composite 
score of age, hyperglycemia, body mass index, platelet count, albumin, and aspartate 
aminotransferase and alanine aminotransferase (AST/ALT) ratio and was found to 
independently identify NAFLD patients with and without advanced fibrosis at initial 
NAFLD diagnosis. Thus, the NFS is composed of 6 variables, including age, 
hyperglycemia, BMI, platelet count, albumin, and AST/ALT ratio as independent 
indicators of advanced liver fibrosis. NAFLD fibrosis score = -1.675 + 0.037 × age 
(year) + 0.094 × BMI (kg/m2) + 1.13 × IFG/diabetes (yes = 1, no = 0) + 0.99 × 
AST/ALT ratio - 0.013 × platelet count (×10
9
/L) - 0.66 × albumin(g/dL). According to 
the results obtained, subjects were differentiated according the following parameters: 
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NFS <-1.5 for low, NFS ≥ -1.5 to NFS < 0.67 for intermediate and NFS ≥ 0.67 for high 
probability of fibrosis (Angulo et al., 2007) 
3.4.2.9 Hepatic Insulin Clearance  
 Hepatic insulin clearance can be estimated using simple measurements of the 
ratio of C-peptide to insulin, based on the assumption that C-peptide is secreted by 
pancreatic β-cells in equal amounts with insulin; however, unlike insulin, C-peptide is 
not extracted by the liver and has a constant peripheral clearance. Due to the different 
elimination kinetics of insulin and C-peptide, the C-peptide/insulin ratio can be used to 
estimate the amount of insulin that was clear in the liver. However this estimation is 
more feasible during steady-state conditions, eg, in the fasting state, whereas the 
estimation of insulin clearance during non-steady-state conditions requires modeling of 
C-peptide kinetics to calculate pre-hepatic insulin secretion rates to which peripheral 
insulin can be compared. However the models that will allow us to do that evaluation 
have been being developed. For estimating insulin clearance, the molar ratio of C-
peptide over insulin was calculated from the plasma levels at each time and from the 
total areas under the respective concentration curves (Meier et al., 2007).  
3.4.2.10 BioBank 
 In order to realize future investigations, all the blood samples analyzed were 
distributed by different Eppendorfs according to the amount of serum or whole blood 
remained after the analysis, and stored at – 80ºc.  
3.5 Statistical analysis 
 In study 1 the calculation of odds ratio was performed to access to the risk of 
developing diabetes according to type of F.H.D. In order to evaluate if the analyzed 
populations displayed a gaussian distribution a Shapiro–Wilknormality test was 
performed (p<0.05). The average age between the different groups of diabetics as well 
as between the genders within the LADA, T1D and T2D subjects was analyzed by 
Mann Whitney test (p<0.05). In study 2 due to the small size of population was not 
possible to perform statistical analysis. 
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4. Results 
4.1 Study 1  
 Analyzing the age distribution in the three different populations it was possible 
to observe that in T1D (Fig. 7) the higher density of population was located below the 
50 years (72.52%), while in T2D (Fig 8) the majority of individuals were located after 
60 years (76.45%) . The LADA population (Fig 9) has shown an intermediate behavior 
with the higher group above 70 years and (76.41%). 
 
 
 
 
 
 
 
Figure 7 - Age distribution of T1D subjects. Data are presented in number of individuals distributed in 10 
years categories. 
 
Figure 8 - Age distribution of T2D subjects. Data are presented in number of individuals distributed in 10 
years categories. 
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Figure 9 - Age distribution of LADA subjects. Data are presented in number of individuals distributed in 
10 years categories. 
 
 As the three populations analyzed do not follow Gaussian or Normal distribution 
in the Mann-Whitney test (T1D: p< 0.001; LADA p<0.001; T2D p<0.001), we had to 
use non-parametric tests for the analysis process.  
 The type 1 diabetes group was constituted by 1649 males and 1364 females with 
an average age of 40.73 ± 15.53 (3 – 90 yr. old) and 40.66 ± 16.32 (2 – 98 yr. old), 
respectively. No statistical differences were found between the average ages of the 
genders.  
 The LADA population was the smallest analyzed, with 180 males and 193 
females with an average age of 55.40 ± 13.68 (28 – 85 yr. old) and 60.51± 13.15 (22 – 
100 yr. old), respectively. It was found a statistical difference between these average 
ages of the genders (p< 0.01).  
 The type 2 diabetes population was comprised by 7047 males and 6441 females, 
with an average age of 65.94 ± 10.56 (18 – 97 yr. old) and 67.88 ± 10.81 (19 – 102 yr. 
old), respectively – with a significant difference between these averages. The three 
populations analyzed were statistical different regarding the average age (T1D: 40.70 ± 
15.89 vs LADA: 58.04 ± 13.63 vs T2D: 66.86 ± 10.73; p <0.001).  
 The T1D population had the lowest prevalence of FHD among populations 
analyzed (~50%), with LADA and T2D subjects presenting a prevalence of FHD ~60 
%.       
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Figure 10 - Prevalence of FHD and odds ratio in the three populations analyzed. The prevalence is 
presented in %, while the odds ratio is presented with a 95% confidence interval.    
 
 In TID subjects with F.H.D, second degree relatives were the more prevalent 
group and those who increased most the risk to develop T1D, while for T2D group the 
first-degree relatives showed the same pattern. LADA population displayed a high 
prevalence of first-degree and second degree relatives with diabetes in the family (Fig 
10). T2D was the most prevalent type of diabetes in the relatives of the three types of 
diabetics, however the OR indicated that the type of FHD clearly influence the type of 
diabetes that the subjects are in risk to develop in the future. Presence of T1D in 
relatives increased the risk for T1D, and presence of type 2 relatives increased the risk 
for T2D. It was possible observed too that a FHD that includes relatives with type 1 and 
type 2, therefore a combination of this two types of diabetes in the family, increased the 
risk of develop LADA instead type 1 or type 2 diabetes (Table 9). 
 
Table 9- Type of F.H.D present on T1D, LADA, and T2D subjects. The prevalence is presented in %, 
while the odds ratio is presented with a 95% confidence interval. Only T1D relatives – patient of APDP 
with a FHD only composed by type 1 diabetic. Only T1D relatives – patient of APDP with a FHD 
composed only by type 1 diabetics. T1D and T2D relatives - patient of APDP with FHD composed by 
Diabetic Patients (n= 16874)  
T1D subjects 
N=3013       
17.86% 
LADA subjects 
N=373       
2.21% 
T2D subjects 
N=13488       
79.93% 
With F.H.D (1
st
 
and/or 2nd degree)              
n=1498/3013               
49.72%                   
OR= 0.69 (0.64 – 
0.75) 
Without F.H.D 
(1st and/or 2nd 
degree) 
n=1515/3013                
50.28% 
With F.H.D (1st 
and/or 2nd 
degree) 
n=224/373                
60.05%            
OR= 1.13 (0.92-
1.39) 
Without F.H.D 
(1st and/or 2nd 
degree) 
n=149/373                
39.95% 
With F.H.D (1st 
and/or 2nd 
degree) 
n=7923/13488              
58.74%          
OR= 1.39 
(1.28-1.49) 
Without F.H.D 
(1st and/or 2nd 
degree) 
n=5565/13488                
41.26% 
At least 1st 
degree 
relatives 
n=763/3013              
25.31%     
OR = 0.33 
(0.30-0.36)  
At least 1st degree 
relatives 
n=160/373               
42.89%      
OR=0.87 (0.70-
1.07) 
At least 1st 
degree relatives 
n=6859/13488           
50.85%           
OR= 2.77 (2.54 – 
3.00) 
Only 2nd degree 
relatives              
n=1064/13488                
7.89%                   
OR = 0.28 (0.25 – 
0.31) 
Only 2nd degree 
relatives              
n=64/373               
17.16%              
OR = 0.34 (0.26 – 
0.44) 
Only 2nd 
degree 
relatives              
n=735/3013                
24.39%      
OR =3.64 
(3.29-4.04= 
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relatives with T1D and T2D. Only T2D relatives - patient of APDP with a FHD composed only by type 2 
diabetics.  
Family 
history 
of 
diabetes 
Only T1D Relatives T1D and T2D relatives T2D Relatives 
  n  %  OR (95% CI) n  % OR (95% CI)  n   % OR (CI 95%) 
T1D 
patients 
(n=763) 
177 5.87 7.66 (6.03 – 9.74) 69 2.29 2.03 (1.53-2.70) 517 17.16 0.22 (0.20- 0.24) 
LADA 
patients 
(n=160) 
13 3.49 2.12 (1.21 – 3.74) 12 3.22 2.52 (1.39-4.55) 135 36.19 0.74 (0.59-0.91) 
T2D 
patients 
(n=6859) 
99 0.73 0.12 (0.10 – 0.16) 146 1.08 0.44 (0.34-0.59) 6614 49.04 4.04 (3.69-4.43) 
 
 The prevalence and type of diabetes in the parents was a parameter evaluated 
(table 10). The higher prevalence of diabetic parents was found in type 2 patients; 
followed by LADA and type 1 patients. LADA and T2D subjects displayed similar 
results regarding to prevalence, with higher percentage of diabetes in only mothers than 
only fathers (twice times higher) and both parents. In type 1 diabetics, the prevalence 
was nearly equal for only mothers and only fathers with diabetes, and lowest for cases 
with both parents with the disease. The OR indicated for T1D and T2D that just the fact 
that having only one parent with the respective type of diabetes increased the risk of 
development the disease. However for type 1 the risk was higher having only father 
with T1D, while in the case of T2D the risk was higher having only mother with type 
T2D. Having both parents with the same type of diabetes is also a risk factor to develop 
T1D or T2D, depending on the type of diabetes present in these parents. Regarding to 
LADA, it was only found significant OR in the case of having parents with different 
types of diabetes, which was in concordance with results obtained in table 9.    
 
 
 
 
 
Table 10 - Prevalence of diabetes in parents with respective odds ratio. The prevalence is presented in %, 
while the odds ratio is presented with a 95% confidence interval. The data represent the number of 
patients of APDP with different parental history.    
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 It was detected a higher prevalence of diabetes in offspring of people with 
LADA than in the offspring of the other patients with T1D and T2D. Regarding to 
diabetic siblings, the prevalence of those was higher in type 2 diabetic population. It 
was noticed too that the number of siblings affected with diabetes was always larger 
than the offspring in all diabetic groups analyzed, demonstrating a higher prevalence of 
diabetes in siblings than in offspring.  Analyzing the offspring diabetic of people with 
type 1 diabetes, it was possible to observe that type 1 diabetes was more prevalent, 
while in siblings it was found an equal incidence of type 1 or type 2 diabetes. In LADA 
group, the majority of offspring with diabetes were detected with T1D whereas the 
majority of siblings presented type 2 diabetes. Regarding to offspring and siblings 
diabetics of T2D population, it was clearly observed a higher prevalence of T2D in both 
relatives (Fig 11). 
  
Type of 
diabetics 
T1D patients LADA patients T2D patients 
Parental 
history 
N % OR N % OR n % OR 
Without 
parental 
diabetics 
2428 80.58 - 257 68.90 - 8301 61.54 - 
With 
Parental 
Diabetics 
585 19.42 0.39(0.35-0.43) 116 31.10 0.84 (0.67 – 1.05) 5187 38.46 2.39 (2.19 – 2.62) 
Only 
father 
with DM 
252 8.36 0.14 (0.12-0.16) 31 8.31 0.73 (0.50- 1.05) 1580 11.71 1.46(1.28-1.66) 
T1D 42 1.39 8.89 (5.30-14.91) 2 0.54 1.43 (0.35 – 5.87) 20 0.15 0.11 (0.07-0.19) 
T2D 210 6.97 0.58 (0.50 - 0.67) 29 7.7 0.70 (0.48 -1.03) 1560 11.57 1.72 (1.49-1.98) 
Only 
mother 
with DM 
264 8.76 0.38 (0.33 - 0.43) 61 16.35 0.87 (0.66-1.15) 2765 20.50 2.43 (2.15-2.74) 
T1D 29 0.96 3.63 (2.23 – 5.91) 2 0.54 1.38 (0.34 – 5.68) 35 0.26 0.28 (0.17 – 0.48) 
T2D 235 7.80 0.34 (0.29 – 0.39) 59 15.82 0.86 (0.64 – 1.14) 2730 20.24 2.67 (2.35 – 3.03) 
Both 
parents 
with 
diabetes 
69 2.29 0.35 (0.27 – 0.45) 24 6.43 1.18 (0.77 – 1.79) 842 6.24 2.36 (1.89 – 2.93) 
T1D 4 0.13 3.68(0.99-13.72) - - - 5 0.04 0.31 (0.08 – 1.17) 
T2D 59 1.96 0.30 (0.23 – 0.40) 22 5.90 1.09 (0.71 – 1.79) 836 6.20 2.69 (2.14 – 3.40) 
With 
different 
types of 
DM 
6 0.20 3.46 (1.20-9.97) 2 0.54 11.11(2.35-52.52) 6 0.04 0.19 (0.07 – 0.54) 
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T1D 
Siblings with 
DM 
n=257/3013        
8.53% 
Siblings T1D 
n=122/3013      
4.05% 
Siblings T1D 
and T2D 
n=11/3013   
0.37% 
Siblings T2D        
n=124/3013  
 4.05% 
Siblings without 
DM     
n=2756/3013 
 91.47% 
Offspring 
with DM 
n=65/3013         
2.16% 
Offspring 
T1D 
n=50/3013 
1.66% 
Offspring 
T1D and 
T2D 
n=1/3013 
 0.03% 
Offspring 
T2D        
n=14/3013  
0.46% 
Offspring without 
DM     
n=2948/3013  
97.84% 
LADA 
Siblings with 
DM 
n=70/373          
18.77% 
Siblings T1D 
n=8/373) 
2.14% 
Siblings T1D 
and T2D 
n=1/373   
0.27% 
Siblings T2D        
n=61/373   
16.35% 
Siblings without 
DM       n=303/373   
 81.23% 
Offspring 
with DM         
n=17/373             
4.56% 
Offspring 
T1D 
n=12/373 
3.22% 
Offspring 
T1D and T2D 
(n=2/373)   
0.54% 
Offspring 
T2D        
n=3/373   
0.80% 
Offspring without 
DM         
n=356/373     
95.44% 
T2D 
Siblings with DM 
n=3571/13488        
26.58% 
Siblings T1D 
n=50/13488  
0.37% 
Siblings T1D 
and T2D 
n=38/13488 
0.28% 
Siblings T2D        
n=3497/1348
8       
25.93% 
Siblings without 
DM  
n=9903/13488     
  73.42% 
Offspring with 
DM   
n=565/13488        
4.19% 
Offspring 
T1D 
n=89/13488  
0.66% 
Offspring 
T1D and T2D 
n=14/13488  
0.10% 
Offspring T2D 
n=462/13488   
 3.43% 
Offspring without 
DM    
n=12880/13445        
95.81% 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11- Prevalence of diabetes in siblings and offspring of people with T1D, LADA or T2D. The 
prevalence is presented in %. Siblings T1D – patient of APDP with type 1 diabetic siblings; Siblings T1D 
and T2D – patient of APDP with at least two siblings, one with T1D and other with T2D; Siblings T2D – 
patient of APDP with type 2 diabetic siblings. 
  
61 
 
 
 In order to further evaluate the impact of first-degree relatives with diabetes as 
risk factor to develop T1D, LADA or T2D, we analyzed specifically only siblings and 
parents. As was explained below, the subjects that we had access to all information 
regarding to F.H.D were the people only with first-degree relatives with diabetes. Thus, 
we decided access this variable only in this people, removing possible alterations caused 
by the presence of second-degree relatives with diabetes. The results indicated that the 
simply presence of first-degree relative increased the risk of develop diabetes. However, 
once again, the type of diabetes present in relatives clearly influences the disease that 
people are in risk to develop: first-degree relatives with T1D increase the risk to develop 
T1D while the presences of T2D in first-degree relatives increase the risk to develop 
T2D. No significant OR was found in LADA population, probably due the small size of 
the sample. The prevalence was higher in only parents group in both types of diabetes, 
but regarding OR, was noticed  that among the first-degree relatives of people with 
diabetes, the presence of diabetes in siblings are indeed the higher risk factor to develop 
the disease (Table 3.3). This effect was specially observed in T1D population with an 
OR of 14.01 (95 %IC: 7.94 – 24.70).   
4.2 Study 2 
 
 After the first part of this study, it was concluded that in fact the siblings of type 
2 diabetics are a high risk group to develop the disease, not only due the OR obtained 
         Relatives 
with Diabetes  
 T1D 
  
  
     (n)              %                OR (95% IC) 
 LADA 
  
  
 (n)              %                     
OR (95% IC) 
 T2D 
 
  
(n)                %                  OR 
(95% IC) 
Only parents 214 7,10 0.47 (0.41 – 0.54) 51 13,67 1.09 (0.81 – 
1.46) 
1887 13,99 1.92 (1.67 – 
2.19) 
Only Siblings 82 2,72 0.36 (0.29 -0.45) 17 4,56 0.70 (0.43 – 
1.14) 
971 7,20 2.58 (2.09 – 
3.18) 
Only siblings 
with T1D 
48 1,59 14.01 (7.94 – 24.70) 3 0.80 2.19 (0.54 – 
6.23) 
13 0.10 0.06 (0.03-
0.12) 
Only Siblings 
with T2D 
31 1,03 0.14 (0.10 – 0.20) 14 3.75 0.62 (0.36 – 
1.06) 
950 7.04 5.63 (4.16 – 
7.60) 
Only Siblings 
with T1D and 
T2D 
2 0,07 1.15 (0.24 – 5.42) 0 0 - 8 0.06 1.01 (0.21 – 
4.75) 
Parents and 
Siblings 
59 1,96 0.20 (0.16 – 0.26) 22 1,07 0.74 (0.48 – 
1.15) 
1222 9,06 4.06 (3.24 – 
5.11) 
   
 
Table 11 – Prevalence of diabetes and OR in relatives of diabetics with FHD composed by only first-degree 
relatives. The prevalence is presented in %, while the odds ratio is presented with a 95% confidence interval.       
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but mainly due the higher prevalence of the disease. However, the previous results were 
totally achieved with basis on self-report of patients. Thus, the next step was naturally 
evaluated possible metabolic alterations that could be associated to this higher risk of 
develop diabetes by siblings of type 2 diabetics. In order to achieve this purpose we 
decided to perform an OGTT modified on healthy siblings of T2D patients. This 
procedure allowed in first, categorizes the siblings according to dysglycemic state. It 
was obtained 12 siblings with NGT, 4 with IFG, 1 with IGT, 3 with IFG+IGT and 3 
with T2D. Therefore, among the 23 subjects analyzed, around 50% displayed some 
degree of dysregulation of glucose metabolism. The others parameters assessed in this 
population are described in table 12. 
Table 12 – Characteristics of the Study Population (23 adults aged >18 categorized according to glucose 
tolerance in normal glucose tolerance (NGT), impaired fasting glucose(IFG), impaired glucose tolerance 
(IGT), impaired fasting glucose plus impaired glucose tolerance (IFG+IGT), Type 2 Diabetes  (T2D). 
Abbreviations: BMI - Body mass index; HbA1c - Glycated hemoglobin; LDL - Low-density lipoprotein; 
HDL - high-density lipoprotein; TAG -  Triacylglycerols. 
* The values are expressed in mean ± standard error of mean (SEM) 
 
Variable All subjects NGT IFG IGT IFG+IGT T2D 
Number of 
subjects (%) 
23 (100) 12 (52.17) 4 (17.39) 1 
(4.35) 
3 (13.04) 3 (13.04) 
Age (yrs)* 56.48 ± 
11.13 
55.67 ± 
10.01 
56.5 ± 15.61 69 63.67 ± 6.81 48.33 ± 
11.84 
Gender (M/F) 8/15 3/9 1/3 1/0 1/2 2/1 
Waist 
Circumference 
(cm) (M/F)* 
107.38 ± 
11.02 / 88.87 
± 12.36 
101 ± 15.13 
/ 83.39 ± 
6.76 
110 / 94 ± 
14.73 
105/0 111/92.3±20.79 115 ± 
11.31/116 
BMI(Kg/m2)* 29.70 ± 5.32 29.92 ± 
3.66 
30.11 ± 6.16 30.78 32.27 ± 4.31 37.38 ± 
4.06 
HbA1c %* 5.56 ± 0.89 5.19 ± 0.49 5.48 ± 0.53 5 5.73 ± 0.06 7.2 ± 1.4 
[glucose]0 minutes 
(mg/dL)* 
108.63 ± 
31.40 
92.83 ± 
3.79 
107.28 ± 
6.90 
93.5 115.73 ± 4.47 175.8 ± 
51.36 
[glucose]120 
minutes (mg/dL)* 
138.2 ± 
73.27 
106.23 ± 
16.55 
103.05 ± 
13.91 
152.60 174.27 ± 13.23 298.4 ± 
86.53 
LDL (mg/dL) 138.74± 
34.35 
125.25 ± 
30.15 
150 ± 33.80 171 151.33 ± 25.32 154.3 ± 
56.16 
Total 
cholesterol 
(mg/dL)* 
194.29± 
39.21 
180.07 ± 
34.28 
207.8 ± 
39.73 
225.2 212.63 ± 35.02 204.5 ± 
64.29 
HDL (mg/dL)* 59.38 ± 
33.96 
68.86 ± 
45.05 
51.23 ± 5.91 43 55.33 ± 9.45 41.73 ± 
9.21 
TAG (mg/dL)* 125.58 ± 
54.12 
119.59 ± 
55.26 
124.45 ± 
69.64 
200.9 129.97 ± 70.01 121.57 ± 
12 
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The number of individuals with obesity, central obesity, decreased HDL cholesterol 
level, increased LDL cholesterol levels, higher levels of total cholesterol and 
hypertriglyceridemia in the different groups are represented in table 13.  
 
 
 
 In this study, we examined siblings of diabetic patients aged between 41 and 68 
years old and the average age of the siblings was 56 years old. Analyzing the values of 
waist circumference, and taking in count the cutoffs of IDF (Central obesity for Male: ≥ 
94 cm and for Female ≥ 80 cm), it was possible observe that all the subjects with 
dysregulation of glucose metabolism (prediabetes or diabetes) present values of waist-
circumference above the cutoffs, being this away considered as having central obesity. 
In NGT group, 2 males and 7 females presented central obesity while 1 men and 2 
women presented a waist circumference normal. The BMI average in all groups were 
above the normal values (healthy weight - from 18.5 to 25 Kg/m
2
), with NGT group 
being the only sub-group with values within the excess of weight category and the 
remainders within the obesity category. These results indicated a tendency in siblings to 
have dysregulation of weight control with high levels of obesity, mainly visceral (table 
3.4 and 3.5).  
 Although HbA1c testing is mainly used for monitoring blood sugar control in 
patients with diabetes, the World Health Organization (WHO) now recommends that 
HbA1c can be used as a diagnostic test for diabetes, provided that stringent quality 
assurance tests are in place and assays are standardized to criteria aligned to the 
 Overall  
(n=23) 
NGT 
(n=12) 
IFG 
(n=4) 
IGT 
(n=1) 
IFG+IGT 
(n=3) 
T2D 
(n= 3) 
Overweight 6 4 1 0 1 0 
Obesity 11 3 2 1 2 3 
Central obesity (n) 21 10  4 1 3 3 
Decreased HDL cholesterol  (n) 19 9 4 1 2 3 
Increased LDL cholesterol  (n) 22 11 4 1 3 3 
Higher levels of total cholesterol 
(n) 
9 2 2 1 2 2 
Hypertriglyceridemia (n) 8 4 2 1 1 0 
Table 13 - Prevalence of obesity and lipid profile in the overall population and in each dysglycemic 
categories. 
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international reference values. An HbA1c of 6.5% is recommended as the cut-off point 
for diagnosing diabetes. A value less than 6.5% does not exclude diabetes diagnosed 
using glucose tests. In our study the values of HbA1c, as expected, were above the cut-
off in diabetic patients. Among the individuals in prediabetes state the values were 
higher for IFG+IGT sub-group.  
 Other interesting point that can be highlighting on these results was the fact that 
glucose levels on fasting state for overall population are within the range of prediabetes 
(IFG), while the values at 120 minutes are within the normal range. This is probably due 
the fact that exist a higher prevalence of IFG than IGT among the T2D-siblings.          
 Dyslipidemia is defined as an abnormal amount of lipids (e.g. cholesterol and/or 
fat) in the blood. Dyslipidemias may be manifested by deregulation of several 
parameters as elevation of total cholesterol, low-density lipoprotein (LDL) cholesterol 
and the triglyceride (TAG) concentrations, and a decrease in high-density lipoprotein 
(HDL) cholesterol concentration in the blood. This metabolic disorder contributes 
directly to a high risk of cardiovascular diseases (CVD).  The National Cholesterol 
Education Program Adult Treatment Panel III (NCEP ATP III) stablished the follow 
criteria to dyslipidemia: LDL≥ 100mg/dL; total cholesterol ≥ 200 mg/dL; HDL ≤ 60 
mg/dL; TAG ≥ 150 mg/dL. Taking in consideration these criteria, the overall population 
presented values above the range for LDL and slightly below the recommended for 
HDL. It was in NGT subjects that less deregulation were detected, with only the levels 
of LDL below the cutoff points. In prediabetic and diabetic state, it was observed a 
tendency to increase the levels of TAG, LDL and total cholesterol, and a decrease in 
HDL levels (table 3.5). 
 In the figure 12, 13, 14 it is showed the variation of glucose, insulin and c-
peptide, respectively, during the OGTT. Through the analyses of insulin and c-peptide 
plasma levels it was possible understand the different profiles of insulin secretion in 
different dysglycemic states.  
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The fasting plasma glucose levels of IFG were higher than the glucose levels observed 
in both NGT and IGT sub-groups (IFG: 107.26 vs IGT: 93.5 vs NGT: 92.83 mg/dl). The 
variation of glucose during the OGTT in the IFG group was intermediate between that 
of the normal and impaired glucose-tolerant groups. However, the 2-h plasma glucose 
concentration in the IFG group had returned to values observed in NGT and was 
markedly lower than in the impaired glucose tolerant group. Subjects with IFG+IGT 
had elevated plasma glucose and insulin concentrations, similar to those with IFG, and 
elevated glucose and insulin levels, similar to IGT. Thus, individuals with IFG+IGT 
shared the characteristics of both IFG and IGT.  
 In NGT sub- group, the regular secretion of insulin is showed, with a first phase 
of insulin release occurring in the initial minutes and the correspondent second phase 
occurring in the last minutes of OGTT (Fig 13 and 14).  
Figure 12 - Plasma glucose concentration during the OGTT in different categories. Data are presented 
as mean ± SEM. 
 
Fig. 3.5 Plasma glucose concentration during the OGTT (75g glucose /200 mL H2O) in different 
categories of glucose tolerance. Data are presented as mean ± SEM. 
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In IFG subjects it was possible observe a slightly increase of insulin and c-peptide 
levels in the first 30 minutes, however the higher increase occur in the minute 90 
(probably last phase of insulin release or a delay in first-phase) allowing compensate the 
impaired first-phase and thus decrease glucose levels to normal ranges. In IGT group 
did not occurred such a higher increase as in IFG group at last minutes (Fig 13 and 14), 
which could have, possibly, as consequence higher glucose levels at minute 120 (Fig 
12).  
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It was on IFG+IGT group that was achieved the higher levels of insulin and c-peptide 
secretion, what indicated that being the subjects with the worst glucose regulation 
among the prediabetic individuals, β-cell was probably trying to compensate the higher 
Figure 13 - Plasma insulin concentration during the OGTT in different categories. Data are presented as 
means ± SEM.   
 
Fig 3.6 Plasma insulin concentration during th  OGTT in differe t categories of glucose tolerance. Data 
are presented as means ± SEM.   
 
Figure 14 - C-peptide secretion during the OGTT in different categories. Data are presented as means ± 
SEM. 
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levels of insulin resistance in order to maintain glucose levels below the diabetic range.  
In T2D group it was observed an expected lack of insulin and c-peptide secretion which 
it is a factor responsible for the occurrence of diabetes.  
 The other important process in regulation of insulin levels assessed in this 
project was insulin clearance. Due the fact that c-peptide (kidney) and insulin (liver) are 
cleared in different organs, and due to fact that both are secreted at same time and rate, 
it was possible have an estimation of insulin clearance through the calculation of c-
peptide/insulin ratio plus estimation of area under the curve (AUC).  
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It was aimed that differences in insulin clearance would be related with different 
dysglycemic categories. Analyzing the values of c-peptide/insulin ration during the 
OGTT, it was observed that in feeding state the values of insulin clearance was 
characteristic of each dysglicemic category. It was also detected that the main alteration 
of this process occurred at minute 30 with a higher decrease of HIC, mainly in NGT and 
IFG group (Fig 15). This slope was not so noted in IGT and IGT+IFG and practically 
did not occur on type 2 diabetic (Fig 16). Nevertheless, all the groups diminished the 
hepatic insulin clearance to a value similar.  
Figure 15 - Plasma C-peptide/insulin ratios during the OGTT in different categories. All results are 
presented as means ± SEM.   
 
Fig 3.10 Plasma C-peptide/insulin ratios during the OGTT in different categories of glucose tolerance. 
All results are presented as means ± SEM.   
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Beside the decrease on insulin clearance had be larger on NGT and IFG group, it is 
important understand that a higher ratio of insulin clearance is associated with less 
insulin resistance. The rational of this is just the simple fact that on a NGT subject, 
higher levels of IC means less requirement of insulin to achieve normal glucose levels. 
Thus, our results are in accordance with this theory, with higher levels of insulin 
clearance in NGT group per minute at 30 and 120 minutes and concomitant lower rates 
of this process in prediabetics and mainly in diabetics (Fig 17).  
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During the remainder minutes of OGTT, it was observed an increased on insulin 
clearance in all groups excepted in IFG+IGT group. However the tendency obtained in 
the first 30 minutes was sustained in the course of OGTT, with NGT group having the 
higher values of IC while the ratios of IC were smaller in subjects with abnormal states 
of glucose levels (Fig 15 and Fig 17). Among prediabetics, the AUC120min/min of IFG 
Figure 16 - % of insulin clearance decreased during the first 30 minutes of OGTT in different 
categories. All results are presented as means ± SEM.   
 
Fig 3.11 % of insulin clearance decreased during the first 30 minutes of OGTT in different categorie  
of glucose tolerance. All results are presented as means ± SEM.   
Figure 17-  Insulin clearance per minute during the first 30 minutes and the overall OGTT for different 
categories. All results are presented as means ± SEM.   
 
Fig 3.12 Area under the curve (AUC) of insulin clearance during the first 30 minutes of OGTT in 
different categories of glucose tolerance. All results are presented as means ± SEM.   
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unlike was observed on AUC30min/min, become lower than the values of clearance of 
IGT and IFG+IGT. Comparing the values of AUC30min/min and the values of 
AUC120min/min it was reported that the percentage of hepatic insulin clearance per 
minute was higher during the first 30 min than in the 120 minutes of OGTT, 
highlighting the importance of the decrease of this process in the first 30 minutes of 
OGTT (Fig 3.11).      
 The action of insulin was evaluated by the utilization of OGIS and HOMA-IR. 
According to HOMA-IR (Fig 18), IFG+IGT and IFG group exhibited the highest levels 
of insulin resistance among the prediabetics groups.  
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The results obtained in OGIS (Fig 19) were in concordance with HOMA-IR, with the 
IFG and IFG+IGT group presenting the lower values of insulin sensibility of 
prediabetics. The diabetic subjects displayed the higher values of insulin resistance and 
the lower values of insulin sensitivity, while the NGT were the less resistant and those 
with more insulin sensitivity. 
Figure 18 - Homeostasis model assessment as an index of insulin resistance (HOMA-IR) for different 
categories.  Data are presented as means ± SEM.   
 
 
Fig 3.8 Homeostasis model assessment as an index of insulin resistance (HOMA-IR) for different categories 
of glucos  olerance.  Data are presented as means ± SEM.   
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 Elevated plasma FFA is a common dysregulation in type 2 diabetes and early 
changes may be predictive for the transition of patients from prediabetes states to type 2 
diabetes. These increase on FFA levels on circulation leads to an ectopic accumulation 
on several organs, like liver. Ectopic fat accumulation in the liver is responsible for 
abnormalities like nonalcoholic fatty liver disease (NAFLD), which is the most 
common cause of chronic liver disease in Western countries. Ectopic liver lipid, 
exacerbates hepatic insulin resistance, promotes systemic inflammation, and increases 
risk of developing both type 2 diabetes mellitus and cardiovascular disease. In our 
results, the levels of FFA in the fasting state were high mainly in IFG+IGT group.  
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Figure 20 - Free Fatty Acid plasma levels during the OGTT in different categories. Data are presented 
as means ± SEM. 
 
Fig 3.14 Free Fatty Acid plasma levels during the OGTT in different categories of glucose tolerance. 
Data are presented as means ± SEM. 
Figure 19 - Oral Glucose Insulin Sensitivity (OGIS) for different categories. Data are presented as 
means ± SEM. 
 
Fig 3.9 Oral Glucose Insulin Sensitivity (OGIS) for different categories of glucose tolerance. Data are 
presented as means ± SEM. 
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After the first 30 minutes, it was reported a higher increase of FFA levels on type 2 
diabetes, while the levels of FFA on the other subjects decreased. Nevertheless at this 
point the FFA levels of IFG+IGT and IFG group were yet higher than IGT and NGT. 
With the continuation of OGTT, the levels of FFA decreased in all groups to similar 
levels while the levels of T2D remained high (Fig 20). 
 In order to assess the risk of fatty liver and liver fibrosis it was used the fatty 
liver index (FLI) and NAFLD fibrosis score (NFS), respectively. The results of FLI 
indicated that only 4 out of 23 siblings analyzed had low risk of fatty liver. The group 
with the lower FLI average was NGT subjects, followed by IFG, IFG+IGT, IGT 
subjects and finally with the higher FLI values the type 2 diabetics. The tendency here 
observed with these preliminary results was that with deterioration of glucose levels the 
number of subjects with high risk of fatty liver disease increases (Fig 21).  
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 Regarding to NFS, it was observed a high number of NGT individuals (10 out of 
12) within a range of low probability of liver fibrosis. In the remains groups the 
majority of individuals were located in the middle probability of liver fibrosis range 
(Fig 22). 
 
Figure 21 - Fatty liver index (FLI) for different categories . This data are presented as means ± SEM. 
The number of individuals within each category of FLI is presented in the figure. FLI≤20, with a very 
low risk for fatty liver; 20 < FLI < 60, with an intermediate risk for fatty liver; and FLI ≥ 60 with the 
high risk for fatty liver. 
 
Fig 3.15 Fatty liver index (FLI) for different categories of glucose tolerance. This data are presented 
as means ± SEM. The number of individuals within each category of FLI is presented in the figure. 
FLI≤20, with a very low risk for fatty liver; 20 < FLI < 60, with an intermediate risk for fatty liver; and FLI 
≥ 60 with the high risk for fatty liver. 
Low risk            3  1         0  0        0   
Intermediate risk          8  1                     0  1        0 
High risk           1  2         1  2        3 
 
 
 
Low risk            3  1         0  0        0   
Intermediate risk          8  1                     0  1        0 
High risk           1  2         1  2        3 
 
 
72 
 
N
F
S
N G T IF G IG T IF G  +  IG T T 2 D  
-3 .0
-2 .5
-2 .0
-1 .5
-1 .0
-0 .5
0 .0
0 .5
1 .0
N G T  (n = 1 2 )
IF G (n = 4 )
IG T  (n = 1 )
IF G + IG T  (n = 3 )
T 2 D  (n = 3 )
 
 
 
 
5. Discussion 
 Diabetes is a group of metabolic diseases characterized by hyperglycemia 
resulting from defects in insulin secretion, insulin action, and insulin clearance. The 
chronic hyperglycemia of diabetes is associated with long-term damage, dysfunction, 
and failure of different organs, especially the eyes, kidneys, nerves, heart, and blood 
vessels. There are several risk factors that could lead to dysregulations of glucose 
metabolism with the worst scenario being the development of diabetes mellitus. Among 
these, family history of diabetes can be highlighted. A hereditary component of diabetes 
is suggested from a number of studies that assessed the influence of family history of 
diabetes on risk of diabetes (Joseph et al., 2010; Annis et al., 2005). However it has 
been hypothesized that the development of diabetes results from interactions between 
genetic and environmental factors. Family history of diabetes may reflect both genetic 
susceptibility and exposures to possible hazard environmental factors that are shared 
within the family. In our study we did two different approaches to analyze the 
importance of relatives with diabetes as a risk factor to develop the disease. Firstly, we 
used the clinic files of APDP patients to study the prevalence of FHD on the three types 
of diabetes more prevalent in our clinic, type 1 diabetes, LADA and type 2 diabetes. 
Several studies had assess the risk of FHD on these three types of diabetes, however to 
the best of our knowledge no studies had compared directly the risk between them 
Figure 22 - NAFLD fibrosis score (NFS) for different categories. This data are presented as means ± 
SEM. The number of individuals within each category of NFS is presented in the figure. NFS ≤ -1.5 for 
low probability of fibrosis, - 1.5 < NFS < 0.67 for Intermediate probability of fibrosis, and NFS > 0.67 
for high probability of fibrosis. 
 
Fig 3.16 NAFLD fibrosis score (NFS) for different categories of glucose tolerance. This data are 
presented as means ± SEM. The number of individuals within each category of NFS is presented in the 
figure. NFS ≤ -1.5 for low probability of fibrosis, - 1.5 < NFS < 0.67 for Intermediate probability of 
fibrosis, and NFS > 0.67 for high probability of fibrosis. 
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according to type of FHD present in relatives. Therefore the OR calculated represented 
the probability of determinate subjects develop one type of diabetes instead the others 
types of diabetes evaluated. The study 2 was performed with basis on the results 
obtained in study 1. It was concluded that in fact the siblings of T1D and T2D are a high 
risk group to develop the disease, however it was reported a higher prevalence of 
siblings with T2D in all patients analyzed. Furthermore, all the results obtained in the 
first part were self-reported, which naturally were associated with some percentage of 
bias. Thus, we further evaluated possible metabolic alterations on siblings of type 2 
diabetics that could be associated to a higher risk of these group develop diabetes.  
5.1 Study 1 
 It was detected significant differences regarding to average age of three types of 
diabetics analyzed. This difference can be explained by the different age of onset 
characteristic of each disease, with type 1 diabetes occurring mainly during the 
childhood (Lebenthal et al., 2010), LADA occurring after the 35 years (Naik et al., 
2009), and T2D developing mainly in advanced age (Wikner et al., 2013). Therefore the 
results are in accordance with the expected, being the T2D population the older, follow 
by LADA and T1D population. Among the genders, it was detected significant 
differences regarding to average age in LADA and T2D group, however our goal was 
evaluate FHD in overall population and not separately, in spite of these differences have 
been found. Nevertheless, these possible differences among genders will be a subject 
explored in a next future study.         
 As expected the majority of people with diabetes were type 2 diabetics (79.93 
%), with type 1 diabetics (17.86%) being the second more prevalent and LADA 
(2.21%) the lesser. The prevalence of T2D and LADA was lower while the prevalence 
of T1D was higher compared with other studies (Carlsson et al., 2007; Dabelea et al., 
2014). This lower prevalence of LADA was probably due the difficulty of the diagnosis 
of this disease. The T1D and T2D results can be explained by the fact that our 
population was a convenience sample; the subjects attended at APDP are all advanced 
cases of diabetes. Thus, it is normal that the prevalence had some variability when 
comparing with prevalence existence in general populations that includes no distinguish 
cases of diabetes. In our findings it was observed a high prevalence of FHD for all 
diabetics populations which is in accordance with what is found in literature (Carlson et 
al., 2007) (T1D:49.72% vs LADA: 60.05 % vs T2D: 58.84). Regarding  FHD in T1D 
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population, was observed a higher percentage of individuals with second-degree 
relatives, whereas in T2D a higher prevalence of subjects with first-degree relatives was 
found. Concerning to diabetic relatives of LADA individuals, it was observed a high 
prevalence of patients with first-degree relatives although the second-degree relatives 
had high prevalence too when compared with prevalence of second-degree diabetic 
subjects in T2D. The odds ratio indicated a high risk to develop T1D for people with 
second degree relatives affected by diabetes while the risk to develop T2D was elevated 
in the presence of first degree relatives with diabetes. No significant OR was found on 
LADA population likely due the small size of this population. In type 1 diabetic 
population, the larger prevalence of subjects with second-degree relatives was a result 
that is not in accordance with is described in literature (Parkkola et al., 2013). The same 
fact was reported in OR, with the literature pointing the presence of diabetes in first 
relatives as the high risk factor to development of T1D (Weires et al., 2007). However 
we did not had access to information related with the type of second-degree relatives 
involved in FHD, thus in order to better understand this results we will access the 
presence of diabetes in second degree relatives of APDP patients with higher levels of 
specificity. For T2D the prevalence and OR obtained is in accordance with the previous 
publications (Weires et al., 2007).   
 When analyzed the type of diabetes in relatives of each population, it was clear 
that type 2 diabetes was the more prevalent in all the groups analyzed. These results are 
in concordance with other already published, which may indicate a genetic background 
between type 1, type 2 diabetes and LADA (Li et al., 2000). The higher prevalence of 
type 2 diabetics in relatives of LADA patients is also a feature already described 
(Castleden et al., 2006). Nonetheless the important find that can be highlighted in these 
results is the fact that presence of relatives with type 1 and type 2 increases the risk of 
develop LADA. This result enforces the idea already stablished that LADA share 
common features with T1D and T2D.       
 After this general analysis to the population, we analyzed specifically the 
prevalence of diabetes in first-degree relatives, namely parents, siblings and offspring. 
The results regarding to parents confirmed some of information already published. The 
higher prevalence of diabetic parents was found in T2D subjects (38.46%), followed by 
LADA (31.10%) and T1D subjects (19.42%) (Carlson et al., 2007). In T1D population 
it was reported that the higher risk factor to develop T1D was the presence of a type 1 
diabetic father, which was also observed in other studies (Gale & Gillespie, 2010). For 
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type 2 diabetes, on the other hand, it was found that a presence of a mother with T2D 
increase the risk of develop the disease. This maternal effect, thus the higher risk of 
diabetes associated with having a diabetic mother compared to when only the father was 
affected, already was found in several populations (Meiloud et al., 2013; Benrahma et 
al., 2011). For LADA population the main important achievement was again the fact 
that the risk increase in the presence of relatives, in this particular case parents, with 
different types of diabetes. No additional effect were observed in when both parents are 
diabetes in, this is in contrast with previous studies (Wikner et al., 2013). Considering 
the assessment of other first degrees relatives, it was observed a high prevalence of 
diabetes in siblings and offspring of T2D and LADA patients, being the percentage of 
offspring with diabetes even higher in LADA than in type 2 population. These results 
indicated that although LADA is an autoimmune disease like T1D, the inheritability of 
this type of diabetes is more similar with T2D.  
 The evaluation of parents and siblings of subjects with only first-degree relatives 
with diabetes, brought important information. The prevalence was higher in parents for 
both groups of diabetics. However it was noticed that the presence of diabetic siblings 
was the greater risk factor to develop the disease: type 1 diabetic sibling causes 
approximately a 14-fold increased risk of T1D (Redondo et al.,2008), whereas type 2 
diabetic siblings causes approximately a 6-fold increased risk to develop T2D 
(Hemminki et al., 2010). In LADA results due the small size no OR with significant 
were found, but once again regarding to prevalence it was observed similar results with 
T2D subjects.  
 The main limitation in this study was the lack of a control group in order to 
evaluate the risk of diabetes in comparison with healthy subjects. The fact that all the 
subjects had diabetes did not allow us realize statistical processing in prevalence results, 
except the calculation of odds ratio. However the fact that we compared directly the 
three types of diabetes makes this research unique.         
5.2 Study 2 
 Our results are clearly preliminary and the sample needs to be increased in order 
to perform statistical analyses that allow us to achieve significant comparisons among 
the different groups. Nevertheless, it was obtained several important evidences that may 
be used to understand possible metabolic alterations that are associated with high risk of 
diabetes in T2D-siblings.  
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 It is important to understand that the results of family history of diabetes in study 
1 was obtained basis on an interview realized during their first appointment at APDP. 
Thus, it is likely that these can contain some recall bias, once no one of relatives were in 
fact evaluated and the presence of diabetes was only assumed based on a questionnaire. 
In study 2 we performed a metabolic characterization of a high risk group to develop 
diabetes among the first relatives, namely the siblings. First degree relatives are a 
suitable group to perform metabolic studies since they are at inherently higher risk of 
progressing to T2D and are also likely to be more motivated to undergo testing and 
lifestyle changes to prevent T2D. There is evidence that the glucose intolerance of first 
degree relatives is more highly associated with decreased insulin secretion compared to 
the glucose intolerance of subjects without a T2D relative (Janghorbani & Amini, 2010) 
suggesting that glucose dysmetabolism in first degree relatives are more susceptible to 
develop T2D via b-cell failure. However, less is known about the other factors involved 
in glucose dysmetabolism, notably hepatic and peripheral insulin resistance and how 
they interact with defective insulin secretion to generate the T2D phenotype in these 
relatives. Here, hepatic insulin clearance may play an important but hitherto 
uncharacterized role in the coupling of insulin secretion to its hepatic and peripheral 
actions. In first degree relatives there is a fractional decrease in HIC (Emerson et al., 
2009) possibly in response to a reduced b-cell secretion capacity but no clear 
mechanism is unveil. This is expected to potentiate any underlying hepatic insulin 
resistance and further erode the suppression of hepatic glucose production during 
feeding. The additional input of hepatic glucose into the bloodstream places a further 
burden on peripheral insulin actions above and beyond compensating for peripheral 
insulin resistance. In short, the secretion and clearance of insulin and the metabolic 
responses of liver and peripheral tissues are all interconnected components of glycemic 
control and therefore they all contribute directly or indirectly to a given T2D phenotype.   
 The prevalence of NGT in our study was 52.17%, while prediabetes was 34.78% 
(IFG:18.18%; IGT:4.55%; IFG+IGT:13.64%) and diabetes was 13.04%. Comparing our 
results with the results obtained in PREVADIAB study (Gardete-Correia et al., 2010), 
was detected a higher prevalence of prediabetes (34.78 vs 23.20%); and among the 
prediabetics it was observed a higher prevalence of IFG (18.18 vs 8.2%) and IFT+IGT 
(13.64 vs 2.64%), while the percentage of IGT was lower in our findings than in 
Portuguese population (4.55 vs 12.6%); the prevalence of diabetes in our subjects was 
slightly higher (13.04 vs 11.70%). Regarding to HbA1c results obtained, there are some 
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considerations that need to be explored. A consensus statement from an International 
Expert Committee recommended the use of HbA1C levels 6.5% for the diagnosis of 
diabetes. HbA1C levels between 6.0 and 6.5% are proposed to identify individuals at 
high risk of developing diabetes. It may, however, be questioned whether HbA1C is a 
good indicator of glucose in individuals with normal or moderately elevated glucose 
levels and whether it can therefore be used to identify those with intermediate 
hyperglycemia or undiagnosed diabetes (International Expert Committee,2009) . The 
values of HbA1c for the 23 siblings analyzed are not in accordance with the proposed 
values by the International Expert Committee. Among the diabetics diagnosed in our 
study, two had present an HbA1c result of 8.2% and 7.6%, while one of diabetics 
presented a value of 5.8%. This means that in this specific case by the simple analyzes 
of HbA1c would be difficult achieve the diagnosis of diabetes. Nevertheless, in these 
cases is recommended the repetition of HbA1c measure, procedure that was not 
realized.  In the other hand, among the 8 prediabetics siblings in this study, only one 
case presented a HbA1c value above 6.0 cutoff, the remainders were all below this 
value. These results apparently indicated that the utilization of HbA1c to access 
individuals with prediabetes need to be better evaluated. 
 In our findings it was detected a higher BMI and waist circumference average 
than in other preliminary study realized with siblings of T2D. The lipid profile in the 
siblings analyzed in this study was also worse than in that previous study (Purnamasari, 
et al., 2010). Our results showed a high prevalence of overweight (26.09%) and obesity 
(47.82%). As expected the higher prevalence of obesity were observed in prediabetics 
and diabetics, strengthening the already know connection between obesity and T2D 
(Tharkar & Viswanathan, 2010). The values of obesity obtained in our study are clearly 
higher than the prevalence of obesity in Portuguese population (47.82 vs 24.00%) 
(WHO, 2013). Thus, along with the reported that the majority of the individuals 
analyzed had central obesity (91.30%), may be concluded that the siblings of type 2 
diabetics have a susceptibility to develop obesity, mainly visceral (related with insulin 
resistance and fatty liver). Regarding to lipid profile, the major deregulations detected in 
overall population were the high levels of LDL cholesterol (95.65%) and the low levels 
of HDL cholesterol (82.61%). When the average of each lipid parameter was evaluated, 
it was noticed in prediabetics and in diabetics, a tendency to increase the levels LDL 
and total cholesterol, as well as a decrease in HDL levels when compared with NGT 
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group. These results demonstrated the risk of CVD in prediabetic and diabetic states 
(Pfister et al., 2011). 
 An interesting fact reported was the average glucose level at 0 and 120 minutes 
for overall population, with these values being compatible with the IFG known profile. 
As the IFG are more related with a hepatic insulin resistance, this result seems to 
suggest that the insulin resistance in siblings of type 2 diabetics is mostly hepatic.      
 The glucose levels obtained for the different degrees of glucose tolerance in 
OGTT are the mirror of different defects involve in each glucose dysregulation. It is 
known that people with isolated IFG predominantly have hepatic insulin resistance and 
normal muscle insulin sensitivity, whereas individuals with isolated IGT have normal to 
slightly reduced hepatic insulin sensitivity and moderate to severe muscle insulin 
resistance. Not surprisingly, individuals with both IFG and IGT manifest both muscle 
and hepatic insulin resistance. The pattern of insulin levels also differs between IFG and 
IGT. IFG subjects have a decrease in insulin bioavailability in the first-phase (0-30 min) 
throughout the oral glucose tolerance test. However, the later phase of plasma insulin 
secretion (60-120) during the OGTT remains preserved, allowing the decrease of insulin 
levels to normal range. Isolated IGT also has a defect in early- insulin levels in response 
to an oral glucose load and in addition has a severe deficit in insulin bioavailable in the 
last phase. The high levels of hepatic insulin resistance in isolated IFG results in 
excessive fasting hepatic glucose production accounting for fasting hyperglycemia. 
However, in the OGTT preservation of late insulin response combined with normal 
muscle insulin sensitivity allows glucose levels to return to the preload value in isolated 
IFG. In contrast, in isolated IGT the defective late insulin secretion, combined with 
muscle and hepatic insulin resistance, results in prolonged hyperglycemia after a 
glucose load. In order to evaluate the bioavailability of insulin in our patients we had 
access the levels of insulin and c-peptide in the blood. In spite of insulin and c-peptide 
are equimolar releases, the longer half-life (5 min vs 30 min) and renal clearance of c-
peptide, make it an attractive and more reliable parameter to estimate insulin secretion 
and ß-cell function(Nathan, et al.,2007). In IFG and IGT group the increase in insulin 
levels in the first 30 minutes was lower compared with NGT group (IFG: ratio 
[Insulin]30min/[Insulin]0 min = 4.49 vs IGT= 5.84 vs NGT = 11-fold; IFG: [c-
peptide]30min/[c-peptide]0min=1.93 vs IGT=2.69 vs NGT = 4.06-fold). By definition, 
subjects with IFG had significantly elevated fasting plasma glucose compared with 
normal and impaired glucose-tolerant subjects, and their fasting plasma insulin 
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concentration was higher than the value in NGT and IGT(Abdul-Ghani et al., 2006; 
Rhee & Woo, 2011). In our results the insulin and c-peptide levels were similar with 
IGT, however we are not able to make any conclusion in relation to this group as there 
is the need to evaluate an higher number of subjects. After the minute 30, a high 
released of insulin in IFG group along with normal muscle insulin sensitivity, allowed 
compensate the lowers initial levels of insulin release and thus decrease glucose levels. 
This increase was not so marked in IGT and NGT (IFG: ratio [Insulin]90min/[Insulin]30 
min = 1.70 vs IGT = 0.86 vs NGT = 0.74; IFG: ratio [c-peptide]90min/[c-peptide]30 
min=1.93 vs IGT=1.24 vs NGT=1.08).  In IGT subject due to a not enough level of 
insulin bioavailable and/or high levels of muscle insulin resistance, the plasma glucose 
concentration continued to increase after 30 min and remained elevated at 120 min. In 
IFG+IGT group it was noted an initial increased of insulin levels similar with IGT 
group (IFG+IGT: ratio [Insulin]30min/[Insulin]0 min=4.55; [c-peptide]30min/[c-peptide]0min= 
2.43), and a later insulin release higher than in the others groups evaluated. However, 
even with this larger secretion of insulin, it was observed that the glucose levels remain 
high. This likely had happen due the higher levels of insulin resistance (as demonstrated 
by HOMA-IR and OGIS) in comparison with IFG and IGT group. Individuals with 
IFG+IGT, as can be viewed in our results, start with a high fasting plasma glucose 
concentration because of insulin resistance (see HOMA-IR). It was also noted the 
greatest rise (among prediabetics) in plasma glucose concentration during the OGTT 
likely due a muscle (and hepatic) insulin resistance (Abdul-Ghani et al., 2006). Thus, in 
order to maintain glucoses levels below the diabetic range, the organism possible tried 
to over the resistance by increasing the insulin bioavailability. In type 2 diabetics as 
expected it was observed lowers levels of insulin secretion, as well as lowers levels of 
c-peptide, demonstrating the loss of capacity of β-cell to maintain glucose homeostasis 
(Kanat et al., 2012).   
    The insulin action was also a parameter evaluated in our study, with the 
utilization of HOMA-IR and OGIS. The HOMA-IR index is derived from the product 
of the fasting plasma glucose and insulin concentrations. Since hepatic glucose 
production is the primary determinant of the fasting plasma glucose concentration, and 
the fasting plasma insulin concentration is a regulator of hepatic glucose production, the 
product of fasting plasma glucose and FPI primarily reflects hepatic insulin resistance 
(Esteghamati et al., 2011). The OGIS is a method for the assessment of insulin 
sensitivity from the OGTT. OGIS provides an index that correlates to the index of 
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insulin sensitivity obtained from the the Hyperinsulinemic Euglycemic Clamp. OGIS 
exploits the known quantitative relationships between the observed data and the HIEC 
insulin sensitivity to attempt a genuine insulin sensitivity prediction. Thus, this method 
allow evaluated the sensitivity peripheral to insulin action not only in the fasting state 
but also during the OGGT (Patarrão et al., 2014). When HOMA-IR was used to access 
the insulin resistance, IFG and IFG+IGT subjects were found to be markedly insulin 
resistant compared with subjects with IGT and NGT. This result is in accordance with 
other studies (Kanat et al., 2012; Abdul-Ghani et al., 2006), with IFG and IFG+IGT 
having high levels of hepatic insulin resistance, contributing this way to a higher insulin 
and glucose fasting levels, increasing the HOMA-IR value. As the resistance in IGT is 
essentially in skeletal muscle, the levels of glucose in fasting are lower as well as 
insulin, leading to a smaller value of HOMA-IR. The NGT as expected presented the 
lower value of resistance whereas the type 2 diabetics presented the higher values. 
Regarding to OGIS, the same pattern were observed, agreeing with the values obtained 
in HOMA-IR. The IFG+IGT and IFG presented lowest sensibility when compared with 
IGT. The NGT was the group with higher sensibility and the type 2 diabetics the lowest 
sensibility to insulin action.  
 Regarding to insulin clearance, this is a theme that have been underexplored by 
scientific community, but we believe that its evaluation is essential to further understand 
the metabolic alterations involved in type 2 diabetes. Insulin clearance is a highly 
heritable trait (Goodarzi et al., 2005), raising the possibility that genetic determinants of 
insulin clearance may affect risk for hyperinsulinemic disorders such as diabetes 
mellitus or polycystic ovary syndrome. We aimed that alterations on insulin clearance 
during an OGTT would allow differentiates metabolic states between dysglycemic 
categories. The importance of this process is fundamentally supported by the fact that 
hepatic insulin clearance regulates the insulin bioavailable. A higher rate of HIC is 
responsible for lower insulin levels, while a decrease on clearance leads to higher levels 
of insulin in circulation. These alterations in different physiological or 
physiopatological states can be absolutely fundamental to maintain glucose homeostasis 
and possible are characteristic of each dysglycemic categories. At fasting state the 
values of HIC was different in all groups, with higher levels of clearance in NGT group 
and lower levels in people with type 2 diabetes (suppressed 47.76%). In prediabetic 
states the suppression comparing with NGT group was 13.78, 21.15 and 27.88% for 
IFG, IGT and IFG+IGT group. These results it is in accordance with other studies that 
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related the reduction of HIC with an impaired glycemic control and type 2 diabetes 
(Kotronen et al., 2008). However the reasons that are involve in the reduction of this 
process need yet to be further investigated.  
 In our results, the main alteration in hepatic insulin clearance was observed at 
minute 30, with a decrease in all groups. This reduction is explained by regulation of 
insulin levels according to requirements of organism: in a fasting state there is no such 
necessity of insulin, and thus the hepatic insulin clearance is higher; however after a 
load of 75g glucose, the requirement of insulin naturally increases which is achieve by a 
reduction of insulin clearance, allowing a higher bioavailability of insulin levels (Lee et 
al., 2013). This reduction was higher in NGT and IFG group, while the percentage of 
HIC decreased was lower in IGT and IFG+IGT and was minimal in type 2 diabetics. 
Therefore the groups with higher reductions at 30 min were those that presented lower 
glucose levels in the end of OGTT. These results suggest that a lower decrease of IC in 
the first 30 min is related with abnormal glucose tolerance states. In T2D the reduction 
was minimal; fact that again reinforces that lowers reductions of IC in the first 30 min 
of OGTT are associated with impaired glucose regulation. These results are in 
concordance with our unpublished results. The reason why lower reductions of IC at 
minute 30 are apparently related with dysregulations in glucose homeostasis is not yet 
understood and need further investigation. Nevertheless, this fact can be related with 
lost of the first phase of insulin release, that was already be reported has an important 
defect first defect in T2D (Seino et al, 2011). The importance of HIC in the first 30 
minutes was further reinforced when compared the values of AUC0-30min/min and AUC0-
120min/min, with higher percentage of hepatic insulin clearance per minute during the 
first 30 min than in the overall OGTT.  The main difference that is noted between the 
values of AUC0-30 minutes/min and AUC0-120 minutes/min is that IFG in this analyzes is the 
prediabetic group with the lower rate of HIC, unlike in AUC0-30 minutes/min. This reduction 
was due the fact that HIC almost did not increased between 30 and 90 min, process that 
contributed to an insulin spike at 90 min, thus allowing decrease the glucose levels to a 
normal range. In IGT this reduction was not so markedly. However in this subject was 
observed a reduction in comparison with NGT group, which may be related with 
attempt of increase insulin levels in order to compensate resistance state. 
 Our results are in accordance with several publications that relate lower rates of 
HIC to insulin resistance (Kotronen et al., 2008). Among the prediabetics groups it was 
noted a higher AUC0-30 minutes/min value on IFG group; this fact explains the lowers 
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levels of insulin bioavailable in IFG subjects at minute 30 comparing with IFG and 
IFG+IGT group. The type 2 diabetic displayed the lower rate of insulin clearance, 
which indicates a possible mechanism compensatory to maintain insulin levels as higher 
as possible, taking in count that secretion of β-cell at this point is impaired. In the rest of 
OGTT it was noticed in the majority of the groups an increase in hepatic insulin 
clearance, due the fact that insulin requirement decreased (similar to our unpublished 
results).  
 Insulin is a critical regulator of virtually all aspects of adipocyte biology, and 
adipocytes are one of the most highly insulin-responsive cell types. Insulin promotes 
adipocyte triglyceride stores by a number of mechanisms, including fostering the 
differentiation of preadipocytes to adipocytes and, in mature adipocytes, stimulating 
glucose transport and triglyceride synthesis (lipogenesis), as well as inhibiting lipolysis. 
Insulin also increases the uptake of fatty acids derived from circulating lipoproteins by 
stimulating lipoprotein lipase activity in adipose tissue. Thus, after a meal, insulin 
suppresses lipolysis through the activation of its downstream kinase. During insulin 
resistance, this process is ineffective, and levels of FFA remains higher. This is a 
process that has been related with deteriorating of insulin resistance. The increase in 
FFA in the blood stream could promote ectopic fat accumulation in several organs 
(Choi et al., 2010). The fasting FFA levels in our data were higher in IGT+IFG group, 
followed by IFG. Normally, the IGT subjects have higher values of fasting FFA than 
the IFG subjects due the higher levels of fasting insulinemia usually found on IFG 
group allowing a decrease FFA levels (Abdul-Ghani et al., 2008). However in our 
findings, IFG did not present high levels of fasting insulinemia. Thus, this factor along 
with lower values of insulin sensitivity on IFG group may be the reason why fasting 
FFA levels were higher in IFG than in IGT group. Other result are not in agreement 
with the literature regarding the lower FFA levels of the type 2 diabetics (Mai et 
al.,2013). During the rest of OGTT it was possible to report that FFA in prediabetics 
with more insulin resistance (IFG, IFG+IGT) were hardly suppressed. However at 120 
minutes all the prediabetics and the NGT group presented similar values. In type 2 
diabetics due the high insulin resistance the suppression of FFA was not achieve, with 
levels remaining high at the end of OGTT. 
 Nonalcoholic fatty liver disease (NAFLD) is a condition which is characterized 
by abnormal lipid infiltration in liver (steatosis) in the absence of excess alcohol intake; 
it encompasses a spectrum of conditions associated with lipid deposition in hepatocytes. 
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It ranges from steatosis (simple fatty liver), to nonalcoholic steatohepatitis (NASH—
fatty changes with inflammation and hepatocellular injury or fibrosis), to advanced 
fibrosis and cirrhosis. In order to assess the risk of fatty liver and liver fibrosis it was 
used the fatty liver index (FLI) and NAFLD fibrosis score (NFS), respectively. About 
66% of type 2 diabetic patients are reported to have fatty liver (Mai et al., 2013). All our 
patients with type 2 had high probability of fatty liver. In prediabetics, the higher FLI 
value was detected in IGT subject, due the high levels of TAG and BMI compared with 
the others groups. In literature normally is reported a higher FLI in IFG+IGT among the 
prediabetics due the worst lipid profile that these present. In our findings that did not 
was observed. Nevertheless the average FLI of IGT, IFG+IGT and T2D group were 
situated within the range of high risk of fatty liver, fact that agreed with other studies 
that report the risk of fatty liver on these groups (Faghihimani et al., 2013; Rückert et 
al., 2011). Regarding to NFS, no subjects with higher risk of fibrosis were reported in 
our study, which suggest that although exist a higher prevalence of fatty liver, the 
siblings of type 2 diabetics does not seem to progress to fibrosis.  
 Limitations in this study were (1) this study is a preliminary study with a sample 
of only 23 people, which do not allowed perform statistical relationships (2) the results 
displayed higher variability, which created higher difficult in the date analysis (3) the 
results obtained in IGT, with only one subject in this group, were obviously the less 
reliable.      
 
Conclusion/Future work  
  
 Several studies have evaluated the risk of having a positive family history of 
diabetes (FHD) to develop the disease. The Portuguese Diabetes Association (APDP), 
as the main outpatient clinic of diabetes in Portugal, has a large database originated 
from a large number of clinic files, including the FHD of its patients.  
 Due to the existence of this database, it was possible to have a high volume 
sample available. In order to achieve a further knowledge about F.H.D of APDP 
patients we decided to evaluate this variable in a 5 year period (2009 – 2013). 
Furthermore, we directly compared the risk between three different types of diabetes, 
something that to the best of our knowledge is a completely new approach in the 
evaluation of the effect of first-degree diabetic relatives.  
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 With this work it was possible to reinforce the idea that clearly there is a 
background shared between the three types of diabetes, with FHD in T1D, LADA and 
T2D. Type 1 and type 2 diabetes in FHD contribute with different weights to the risk of 
developing diabetes. 
 Type 2 diabetes was the more prevalent either in T1D, LADA and T2D relatives, 
highlighting both the fact that T2D has a much higher prevalence in the general 
population but also is the more inherited type.  
 It was reported too in our study that the type of diabetes present in relatives 
clearly influences the type of diabetes that people are in risk to develop.  Regarding to 
the presence of diabetes in parents, it was observed that having a father with T1D 
significantly increased the risk of develop T1D, while having a mother with T2D 
increased the risk of develop T2D. We have found also significant associations for other 
first degree relatives. Thus, it was clearly demonstrated that first degree relatives of 
people with diabetes represent a high risk factor to develop diabetes. However, among 
first degree relatives of this large group of patients it was observed that in T1D and T2D 
the factor that provide the higher risk to develop diabetes is the presence of a diabetic 
sibling, with a type 1 siblings increasing the risk 11 fold of develop T1D and type 2 
siblings increasing the risk 6 fold of develop T2D. Regarding the LADA group results, 
it was reported a high heterogeneity with the odds ratio being similar to T1D and 
prevalence being similar to T2D. This confirms that LADA shares in fact features with 
T1D and T2D. The higher risk factor to develop this type of diabetes is the presence of 
parents with different types of diabetes (T1D and T2D).  
 Our second hypothesis was confirmed with first degree relatives of people with 
diabetes providing different weight representation of risk for developing diabetes. All 
this information will help the clinicians of APDP to evaluate future cases of diabetes 
according to type of F.H.D observed.  
 In the future the same analysis could be further exploited using a different 
methodological approach - specifically the utilization of a control group without 
diabetes and analyze possible differences between genders.  
 The second study was performed based on the results reported in study 1. It was 
a priori established that the study 2 would be the analysis of a higher risk group for 
develop diabetes among the first-degree relatives. After the results obtained in study 1, 
we decided to evaluate possible metabolic alterations in siblings of type 2 diabetics. The 
results presented are just a preliminary analysis of a first group of people of what is 
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expected to be a larger sample. So we have considered this as a preliminary study, and 
all the results should be interpreted on this basis. It is necessary to increase the number 
of siblings analyzed, mainly in prediabetics and diabetics group in order to clarify all 
the results here reported. Nevertheless, we believe that our findings provided some 
important indicators in the study of this high risk population. It was observed that the 
T2D-siblings have a higher tendency to have obesity, mainly visceral, than the 
population in general. As it is well-known, visceral obesity is the type of obesity more 
related with insulin resistance and type 2 diabetes.   
 Our population displayed too, a high percentage of IFG as well as high glucose 
levels at 0 min. This fact may indicate a prevalence of hepatic insulin resistance among 
the siblings of type 2 diabetics. 
 Regarding to lipid profile, it was observed a high prevalence of decreased HDL 
cholesterol and increased LDL cholesterol in siblings of T2D. The levels of FFA 
detected were also higher in siblings, mainly in prediabetics with IFG and IFG+IGT. 
This occurrence may be related with the visceral obesity – associated with high levels of 
lipolysis probably due insulin resistance. All this circumstances may have contributed to 
the high prevalence of fatty liver reporting in our population. Nevertheless, the siblings 
do not seem to progress to liver fibrosis.         
 The analysis of hepatic insulin clearance, indicated that this process is related 
with an impaired glucose regulation; mainly the reduction reported at minute 30, being 
detected a higher decrease in HIC in NGT and IFG -  only those who have normal 
glucose tolerance; and a lesser decrease in IGT, IFG+IGT and mainly in type 2 
diabetics. The reason why this decrease is so determinant needs yet to be further 
investigated.   
 Due the small population and high variability of our results, the hypothesis 3 
was not confirmed. However, insulin clearance, which is the regulatory process of 
insulin concentration less explored by scientific community, apparently has a promisor 
role in the etiology of different dysglicemic states, and thus may be related with several 
issues found in our results like insulin resistance, visceral obesity, higher percentage of 
free fatty acids and T2D.  
 The next step in this work could be to define glucometabolic and insulin 
secretion and clearance kinetics in more detail for the T2D sibling populations that has 
been categorized as normal, glucose intolerant or T2D by the OGTT to see if it could be 
possible to identify the phenotype that is highly predictive for T2D progression.  
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Appendices  
 
Appendix A – Parameters obtained in the study 2. 
Patient Gender Age 
(yea
rs) 
LDL 
(mg/
dL) 
Total 
choleste
rol 
 
(mg/dL) 
HDL 
(mg/dL) 
TAG 
(mg/
dL) 
AST 
(U/L
) 
ALT 
(U/L
) 
Gama-
GT 
(U/L) 
[Glucos
e] 
0 mim 
(mg/dL) 
[Glucos
e] 
30 min 
(mg/dL) 
[Glucos
e] 
90min 
(mg/dL) 
[Glucos
e] 
120min 
(mg/dL) 
[FFA]  
0min 
(mmol/
L) 
[FFA] 
30 min 
(mmol/
L) 
[FFA]  
90 min 
(mmol/
L) 
 
[FFA] 
120 min 
(mmol/
L) 
 
[Insulin
e] 0 min 
(μU/L) 
[Insulin
e]  30 
min 
(μU/L) 
[Insulin
e]  90 
min 
(μU/L) 
[Insulin
e] 
120min 
(μU/L) 
[C-
peptide 
] 0 min 
(ng/ml) 
[C-
peptide 
] 30 min 
(ng/ml) 
[C-
peptide 
] 90 min 
(ng/ml) 
[C-
peptide 
]        
120 min 
(ng/ml) 
HbA
1c 
(%) 
Heig
ht 
(m) 
Wei
ght 
(Kg) 
Waist 
circumferen
ce 
(cm) 
1 M 68 101 164 56,3 161,
9 
25 19 20 98,5 199,7 137,7 110,4 0,55 0,55 0,25 0,22 4,2 62,5 36,9 20,9 1,97 7,27 8,39 7,27 5,5 1,65 80 106 
2 F 60 101 178,2 75 94,7 19 16 11 90,3 150,5 109,5 84,3 0,42 0,27 0,1 0,09 3,8 71,7 74,9 23,5 2,08 9,41 13,8 8,75 5,5 1,62 55 80 
3 M 49 167 232 54,9 247,
9 
32 34 73 96,5 135,7 154,6 85,7 0,73 0,58 0,28 0,22 4,2 19,9 72,7 11,6 1,97 3,71 10,5 5,21 5,1 1,69 68 84 
4 M 48 129 182,2 49,9 115,
2 
26 28 30 94,9 157 106,1 120,1 0,47 0,37 0,14 0,11 11,3 77,2 27,1 28,7 2,29 8,46 6,95 7,18 5,1 1,82 110 113 
5 M 58 183 236,7 44,2 159,
3 
33 47 32 116,7 170,4 155,7 102,8 0,46 0,51 0,27 0,16 22 72,3 183,1 66,9 5,65 8,83 17,7 12,2 5,2 1,78 103 110 
6 F 55 110 160,7 44,1 152,
7 
22 26 41 88,7 136,1  95,6 0,39 0,33  0,1 9,8 107,3  57,4 2,77 10,2  10,8 5,5 1,57 61,2 85 
7 M 56 180 250,5 59,6 210,
8 
34 44 64 117,8 191  186,6 0,78 0,72  0,17 22,4 55,8  144 3,84 6,58  13,9 5,7 1,72 100,
2 
111 
8 F 57 113 191,1 76 91,5 27 28 20 96 160,2 102,8 105 0,5 0,36 0,06 0,06 10,8 83,5 55,6 66,1 1,97 8,71 8,54 9,65 5,1 1,51 61 85 
9 F 41 87 137,9 51,5 53,3 12 11 10 86,4 109,8 70,5 96,6 0,3 0,2 0,08 0,07 3,8 77,7 20,2 62,6 1,14 7,62 4,15 7,42 3,9 1,6 63 74 
10 F 43 104 159,2 55,9 50,1 20 13 8 88,8 136,6 87,4 88,8 0,33 0,3 0,05 0,06 3,6 57,8 17,1 22,2 1,22 5,93 5,37 5,55 5,2 1,61 60,5 76 
11 F 58 175 246,9 56 203,
2 
39 49 29 106,1 141,5 176,9 119,5 0,48 0,48 0,24 0,13 9,6 43,1 129,8 62,6 2,49 4,4 9,84 8,37 5,7 1,53 88,3 110 
12 F 64 135 135 208,2 157,
6 
18 17 11 94,2 116,3 88,1 139 0,38 0,19 0,07 0,09 8,9 86,3 24,7 49 2,3 10,2 6,4 10 5,3 1,65 71,8 81,5 
13 M 42 201 253 47 108,
5 
18 36 34 233 321,9 473,3 383,5 0,56 0,58 0,69 0,55 15,5 18,2 32,7 29,4 3,13 3,4 5,32 5,05 8,6 1,73 100 107 
14 F 69 132  
4 
44,5 90,1 22 21 21 118,8 242,7 156,9 160,3 0,64 0,49 0,2 0,13 15,7 116,7 123,3 187,3 3,27 10,5 16,4 20,4 5,8 1,58 68,4 81,6 
15 F 36 125 179,3 56,3 49,2 19 11 12 100,1 170,7 136,7 104,4 0,49 0,34 0,09 0,07 10,5 101,1 76,9 66,1 0,81 2,91 2,96 9,84 4,9 1,62 65,4 81 
16 M 62 92 131,6 31,1 124,
1 
20 30 53 160,6 251,8 347,3 301,2 0,25 0,66 0,33 0,69 73,2 52,1 86,6 26 9,8 6,74 9,84 5,46 7,2 1,59 105 123 
17 F 47 174 222,6 43,4 86 48 63 53 94,9 162,9 114,5 118,6 0,41 0,25 0,1 0,08 10,7 115,1 86,4 96,4 2,48 10,2 10,5 10,9 4,9 1,54 66,1 83 
18 F 66 142 206 61,9 89 29 27 33 110,6 189,2 184,1 175,9 0,47 0,38 0,11 0,1 9,7 45,3 34,4 52,5 2,86 7,16 9,55 10,4 5,7 1,5 80 103 
19 F 67 171 235,7 59,1 90,9 25 33 22 94,7 173,8 112,7 115,4 0,15 0,13 0,07 0,07 11,4 202,8 226,5 276,9 2,39 12,9 17,3 18,3 5,3 1,5 68,6 90 
20 M 69 171 225,2 43 200,
9 
19 23 29 93,5 192 156 152,6 0,4 0,3 0,08 0,11 12,5 73 63 51,1 3,07 8,27 10,3 10,7 5 1,71 90 105 
21 F 69 111 162,2 52 133,
3 
19 17 17 90,1 142,1 129,7 115,2 0,35 0,18 0,09 0,06 11,4 71,1 60,4 57,5 2,85 9,02 11,1 12 5,9 1,49 69,8 96 
22 F 74 117 168,3 48,6 86,1 25 23 21 106,2 191,7 78,5 85,5 0,54 0,3 0,1 0,09 6,4 41,7 48,1 26,7 3,09 7,14 14,5 10,1 6,1 1,7 73,3 91 
23 F 41 170 229 47,1 132,
1 
22 37 23 133,7 237,4 220,3 210,5 0,59 0,46 0,14 0,22 19,8 73,5 128,1 103,2 3,02 6,77 11 10,5 5,8 1,56 90,5 116 
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 Appendix B - Parameters calculated in the study 2. 
 
   
 
 
 
Patient 
Glucose 
Tolerance 
BMI (Kg/m2) c-peptide/insulin 
ratio (ng/ μU) 
0 min 
c-peptide/insulin 
ratio (ng/ μU) 
30 min 
c-peptide/insulin 
ratio (ng/ μU) 
90 min 
c-peptide/insulin 
ratio (ng/ μU) 
120 min 
AUC 
(ng c-
peptide/mU 
Insulin)30 min 
AUC 
(ng c-
peptide/mU 
Insulin)120 min 
%of 
insulin 
decrease 
from 0-30 
min 
OGIS 
(ml.min-
1.m-2) 
HOMA-IR FLI NFS 
1 NGT 
29,38 
0,47 0,12 0,23 0,35 8,78 27,72 75,20 414 
1,02 
72,24 -0,33 
2 NGT 
20,96 
0,55 0,13 0,18 0,37 10,18 27,99 76,02 427 
0,85 
7,35 -2,01 
3 NGT 
23,81 
0,47 0,19 0,14 0,45 9,83 28,66 60,25 415 
1,00 
58,68 -1,77 
4 NGT 
33,21 
0,20 0,11 0,26 0,25 4,68 23,26 45,93 396 
2,65 
86,12 -1,99 
5 IFG 32,51 0,26 0,12 0,10 0,18 5,68 16,43 52,44 275 6,34 87,26 -0,43 
6 NGT 
24,83 
0,28 0,10  0,19 5,67 18,41 66,37  2,15 41,82 -3,01 
7 IFG+IGT 33,87 0,17 0,12  0,10 4,34 13,99 31,21  6,52 94,94 -1,47 
8 NGT 
26,75 
0,18 0,10 0,15 0,15 4,30 16,53 42,81 409 2,56 25,61 -2,33 
9 NGT 
24,61 
0,30 0,10 0,21 0,12 5,97 19,94 67,31 466 0,81 
4,93 -1,78 
10 NGT 
23,34 
0,34 0,10 0,31 0,25 6,62 27,58 69,73 485 0,79 
3,73 -2,57 
11 IFG 
37,72 
0,26 0,10 0,08 0,13 5,42 13,90 60,64 327 2,51 94,32 0,17 
12 NGT 26,37 0,26 0,12 0,26 0,20 5,65 23,92 54,26 376 2,07 22,87 -2,02 
13 T2D 
33,41 
0,20 0,197 0,16 0,17 5,83 21,33 7,49 252 8,92 82,76 -2,42 
14 IFG+IGT 27,40 0,21 0,09 0,13 0,11 4,47 14,79 56,80 279 4,61 24,30 -1,66 
15 IFG 24,92 0,08 0,03 0,04 0,15 1,59 6,42 62,69 386 2,60 7,65 -0,82 
16 T2D 
41,53 
0,13 0,13 0,11 0,21 3,95 16,09 3,37 303 29,03 98,19 -1,39 
17 NGT 27,87 0,23 0,09 0,12 0,11 4,81 14,63 61,77 369 2,51 40,70 -2,30 
18 IFG+IGT 
35,56 
0,29 0,16 0,28 0,20 6,79 27,00 46,39 367 2,65 
80,91 -0,97 
19 NGT 30,49 0,21 0,06 0,08 0,07 4,10 10,44 69,66 276 2,67 44,53 -1,81 
20 IGT 30,78 0,25 0,11 0,16 0,21 5,38 19,28 53,87 383 2,89 82,77 0,41 
21 NGT 
31,40 0,25 0,13 0,18 0,21 
5,65 20,86 49,25 423 2,54 
59,98 -0,91 
22 IFG 25,30 0,48 0,17 0,30 0,38 9,81 34,19 64,54 380 1,68 27,42 -0,80 
23 T2D 
37,19 0,15 0,09 0,09 0,10 
3,67 11,82 39,61 255 6,54 92,25 -0,35 
